

<!--
// Original:  Patrick Lewis
// mod: W. Jansen

if (document.layers) {navigator.family = "nn4"}
if (document.all) {navigator.family = "ie4"}
if (window.navigator.userAgent.toLowerCase().match("gecko")) {navigator.family = "gecko"}



descarray = new Array(

/*
:::::::: Texte f&uuml;r die Info-Box ab hier
:::::::: ab hier k&ouml;nnen sie Änderungen vornehmen
:::::::: f&uuml;r jeden PopUp-Text je eine Zeile in Reihenfolge der Links mit Komma am Ende
:::::::: außer beim Letzten (kein Komma)
:::::::: innerhalb der Zeilen keinen Zeilenumbruch
:::::::: WICHTIG !!! innerhalb der Zeilen keine doppelstrichigen Anf&uuml;hrungszeichen
*/

//Ab hier Speakers MerckSerono

//Array 0 = Prof Christian Berne MD
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Prof Christian Berne MD</strong> <br> <i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/merckSerono/Berne.jpg'></td><td>Christian Berne, Professor of Medicine at the University Hospital of Uppsala , Sweden is a specialist in internal medicine and endocrinology. His research combines experimental and clinical approaches to advancing our understanding of diabetes. Professor Berne has published over 200 scientific papers in these fields as well as authoring many reviews and book chapters for textbooks. He is currently the chairman of the board of the Swedish Society for Diabetology.<br><br>Professor Berne was a member of the Council of the European Association for the study of Diabetes (EASD) from 1993-5 and a past member of the EASD programme committee for the 26th,31st, and 42nd annual meetings of EASD in Copenhagen 1990, Stockholm 1995 and Copenhagen 2006. He has also been past member of the clinical programme committee for the IDF meeting in Helsinki in 1997 and member of the European IDDM and NIDDM policy groups for 1993 and 1998 (IDF-WHO) and Hypertension in NIDDM guidelines of 1997 and 2001 (IDF-WHO). He remains the senior medical advisor for the Swedish guidelines for the treatment of diabetes mellitus, a position which he held in 1996-99 and from 2006 onwards to this day.</td></tr></table>",
//Array 1 = Prof Robert E Ratner  MD FACP FACE
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Prof Robert E Ratner  MD FACP FACE</strong><br><i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/merckSerono/Ratner.jpg'></td><td>Bob Ratner is Professor of Medicine at the Division of Endocrinology in the Georgetown University Medical School, Washington, DC, USA. He specialised in internal medicine and endocrinology and metabolism and is currently the Senior Research Scientist at the Medstar Health Research Institute . His research interests cover a wide area but he has played a principal part in the Diabetes Prevention Program Research Group and other diabetes metabolic and clinical outcomes trials such as ActNow, Origin, and Approach. He recently served as the study director for the comparative effectiveness priorities project at the U.S. Institute of Medicine.  He has contributed towards many research papers and textbook chapters and he is an authoritative voice in diabetes and its management.<br><br>Professor Ratner has played a leading role in many societies and currently he is a member of American Diabetes Association and the American Association of Clinical Endocrinologists. He joined the Endocrine Society in 1980 and is a member of the Awards Committee. He was a member of the steering committee of the National Diabetes Education Program from 2001-2007. He remains a member of the US Phamacopoeia Endocrinology Expert Committee and was the recipient of the Distinguished Group Award for the Comparative Effectiveness Research Team issued from the Institute of Medicine.</td></tr></table>",
//Array 2 = Prof Ian W Campbell MD FRCP
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Prof Ian W Campbell MD FRCP</strong><br><i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/merckSerono/Campbell.jpg'></td><td>Ian Campbell is Emeritus Professor of Medicine at the Bute School of Medicine at St Andrews University, St Andrews in Scotland. His research and teaching interests are divided between the University and the Victoria Hospital in Kirkcaldy where he was formerly a consultant physician with a specialist interest in diabetes. Over the years he has published widely with several hundred original articles and textbooks to his name on the management of diabetes and its complications. He is co-editor of the British Journal of Diabetes and Vascular Disease.<br><br>Professor Campbell has been a supportive member of Diabetes UK ,having been a committee member on five occasions. He gave the Arnold Bloom lecture in 2002 entitled 'A diabetic odyssey from research to guidelines'. He has served UKPDS well from 1998 onwards being given the role of chairman to communicate on the headline results in that year and later in 2008 with the reporting of the 10 year post-trial monitoring data. He has been the President of the Scottish Society of Physicians 2005-6. </td></tr></table>",
//Array 3 = Prof William M Hague MD FRCP FRCOG
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Prof William M Hague MD FRCP FRCOG</strong><br><i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/merckSerono/Hague.jpg'></td><td>Bill Hague is Associate Professor at the School of Paediatrics and Reproductive Health at the University of Adelaide, Australia. He is a specialist in obstetric medicine and holds the post of Senior Consultant Physician at the Women and Children's Hospital, North Adelaide. He is also a senior visiting consultant in obstetric medicine at the Queen Elizabeth Hospital and Flinders Medical Centre, Adelaide. His research interests are many, either working alone or in collaboration, but include gestational diabetes -its avoidance and management, clinical outcome studies in pregnancy looking at polymorphisms, metabolic disorders and the control of risk factors such as hypertension. His authoritative knowledge of pregnancy and diabetes are recognised worldwide and he is a frequent communicator at international meetings. He is the author of multiple research articles and a contributor to textbooks on endocrine disorders and pregnancy.<br><br>Professor Hague has held policy making positions in the past and today, including his membership of the Australian National Advisory Committee on Maternal Mortality and Serious Morbidity. He has been a council member of the International Society of Obstetric Medicine representing Australia, is an Honorary member of the Society of Obstetric Medicine of Australia and New Zealand, and holds memberships of the International Societies for the study of Hypertension in Pregnancy, the Australian Diabetes in Pregnancy Society and the Endocrine Society of Australia. </td></tr></table>",
//Array 4 = Prof Polly J Bingley  MD FRCP
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Prof Polly J Bingley  MD FRCP</strong><br><i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/merckSerono/Bingley.jpg'></td><td>Polly Bingley is Professor of Diabetes and Head of the Clinical Science Department at North Bristol, at the University of Bristol in the UK. At the same time, she is Honorary Consultant Physician at Southmead Hospital and the Bristol Royal Infirmary. Her research interests have focused mainly on type 1 diabetes, particularly disease prediction and prevention, and to a lesser extent, on type 2 diabetes and the use of insulin. She has almost 100 publications to her name plus textbooks and chapters on aspects of diabetes.<br><br>Professor Bingley has been actively associated with many collaborative programmes and research committees involved with advancing current knowledge on genetic and immunological aspects of type 1 diabetes such as EURODIAB ACE, ICARUS, and ENDIT. She was, until recently, Chairman of Immunology of the Diabetes Society Autoantibody committee and Coordinator of the IDS/CDC Diabetes Antibody Standardization Program.  She has held Associate Editor positions for Diabetologia (2000-6) and Diabetic Medicine (2000-4), and is now on the Editorial Advisory Boards of Diabetologia and Diabetes. Memberships include Diabetes UK Research Committee (2004-9), the grant research board of the European Foundation for the study of Diabetes/Juvenile Diabetes Research Foundation/NovoNordisk Awards (2004-2008) and the organising committee of the 41st Annual EASD Meeting in Athens in 2005.</td></tr></table>",

//Ab hier Speaker NovoNordisk

//Array 5 = Jens J. Holst, Denmark
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Jens J. Holst</strong><br><i>Denmark</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/novonordisk/Holst.jpg'></td><td>Jens J. Holst is Professor of Medical Physiology at the University of Copenhagen where his teaching experience spans 25 years at undergraduate and postgraduate levels. He has contributed to approximately 1000 scientific publications, including original studies, chapters in textbooks and review articles, and has been a guest lecturer in Europe, Canada, USA and Japan. Professor Holst is a member of the Royal Danish Academy of Science and Letters. He has been the recipient of several awards for his medical research, including the Anders Jahre Award in 1984, the Odd Fellow Award in 1990, the Novo Nordisk Award in 1992, the 'Paul Langerhans Medal' from the German Diabetes Association (GDA) in 2002, and in 2005 he was awarded the Claude Bernard Prize and lectureship of the European Association for the Study of Diabetes (EASD).</td></tr></table>",
//Array 6 = Tina Vilsbøll Copenhagen, Denmark
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Tina Vilsb&oslash;ll</strong><br><i> Copenhagen, Denmark</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/novonordisk/Vilsboll.jpg'></td><td>Tina  Vilsb&oslash;ll, MD DMSc is working at Department of Internal Medicine at Gentofte  Hospital, University of Copenhagen, Denmark where she is a full time clinician  and head of Diabetes Research Division. Her research interests has since 1997  been the incretin hormones of the gut, glucagon-like peptide-1 (GLP-1) and  glucose-dependent insulinotropic polypeptide (GIP), and their role in healthy  subjects and diabetes. In 2004 she defended her doctoral thesis within this  field and she is currently a supervisor for several PhD students and medical  students doing research within the incretin field. She is also an experienced  teacher and act as reviewer for several international journals. Dr Vilsb&oslash;ll has  received several honorary awards for her work.</td></tr></table>",
//Array 7 = Randy J. Seeley, USA
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Randy J. Seeley</strong><br><i>USA</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/novonordisk/Seeley.jpg'></td><td>Randy J. Seeley is Professor of Medicine and holds the Donald C. Harrison Chair at the Department of Internal Medicine, Division of Endocrinology, University of Cincinnati. His work focuses on the actions of various peripheral hormones in the central nervous system (CNS) that serve to regulate food intake, body weight and circulating fuels. In particular, he has studied the numerous hypothalamic and gastrointestinal peptides and their associated receptors that influence both energy intake and peripheral metabolic processes. Professor Seeley has published over 170 peer-reviewed articles, is the author of 14 book chapters and has co-edited a volume on macronutrient selection. He has received several honours including the 2003 Lilly Scientific Achievement Award from The Obesity Society; he is a co-recipient of the 2008 Ernst Oppenheimer Award from The Endocrine Society; and in 2009 he received the Outstanding Scientific Achievement Award from the American Diabetes Association (ADA) for his contribution to diabetes research. </td></tr></table>",
//Array 8 = Dr. Mansoor Husain
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Dr. Mansoor Husain</strong><br><i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/novonordisk/Husain.jpg'></td><td>Dr. Mansoor Husain is an Associate Professor of Medicine, Physiology, and Laboratory Medicine & Pathobiology at the University of Toronto. He is a Career Investigator of the Heart & Stroke Foundation of Ontario (HSFO), and Director of the Heart & Stroke/Richard Lewar Centre for Excellence in Cardiovascular Research at the University of Toronto.<br><br>Dr. Husain's research laboratory is located in the Toronto General Hospital Research Institute, where he explores basic mechanisms of cardiovascular diseases such as hypertension, atherosclerosis and heart failure. His innovative work on the creation and characterization of molecular genetic and experimental models of human disease has been recognized by a Premier's Research Excellence Award.  Dr. Husain's work on the role played by the incretin hormone glucagon-like peptide-1 (GLP-1) in the cardiovascular system is funded by operating grants from the HSFO.<br><br>In addition to his research activities, Dr. Husain is a cardiologist at the University Health Network. He has a general cardiology practice, is an attending physician in the Nuclear Cardiology Laboratories, and is the Associate Director of the Cardiac Intensive Care Unit at the Toronto General Hospital.</td></tr></table>",
//Array 9 = John Buse, MD, PhD
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>John Buse, MD, PhD</strong><br><i>Chapel Hill, USA</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/novonordisk/Buse.jpg'></td><td>John Buse is Professor at the University of North Carolina School of Medicine where he serves as Director of the Diabetes Care Center, Chief of the Division of Endocrinology and Executive Associate Dean for Clinical Research.  His research interests focus on developing prevention and treatment strategies for type 1 and 2 diabetes and their complications. He has authored more than 200 publications and is involved in numerous multicentre clinical trials. Professor Buse is a past President for Medicine and Science at the American Diabetes Association and the 2010 recipient of the Castle Connolly National Physician of the Year award.  </td></tr></table>",
//Array 10 =  Jorge Plutzky
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Jorge Plutzky</strong><br><i> USA</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/novonordisk/Plutzky.jpg'></td><td>Jorge Plutzky is Associate Professor of Medicine at Harvard Medical School and Director of the Vascular Disease Prevention Program, which includes the Lipid/Prevention Clinic and Partners Premature Atherosclerosis Center, all at Brigham and Women's Hospital. Dr Plutzky also directs a science laboratory that investigates mechanisms contributing to the development of atherosclerosis in patients with various metabolic disorders, including diabetes. This work focuses on the transcriptional regulation of vascular responses through nuclear receptors like PPARs. Dr Plutzky and his team have received several major research awards. He was awarded The Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology, and his laboratory received the Louis N. and Arnold M. Katz Basic Science Prize from the American Heart Association. </td></tr></table>",
//Array 11 =  Stephen Gough
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Stephen Gough</strong><br><i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/novonordisk/Gough.jpg'></td><td>Stephen Gough has recently joined the Oxford Centre for Diabetes Endocrinology and Metabolism, at the University of Oxford. Previously he was Professor of Medicine at the University of Birmingham and Consultant Physician with a special interest in diabetes at the University Hospitals Birmingham NHS Foundation Trust. Professor Gough leads an active diabetes research group with regular peer reviewed publications. His research interests include genetics of autoimmunity and he is a member of the UK National Wellcome Trust Case Control Consortium (WTCCC) for genetic studies in common diseases. As part of his move to Oxford, Professor Gough has established a new translational research group within the Oxford Diabetes Trials Unit conducting early phase trials of novel diabetes molecules and devices. </td></tr></table>",
//Array 12 =  Richard Pratley
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Richard Pratley</strong><br><i>Colchester, VT, USA</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/novonordisk/Pratley.jpg'></td><td>Richard Pratley is Professor of Medicine and Director of the Diabetes and Metabolism Translational Medicine Unit at the University of Vermont College of Medicine. Professor Pratley has led many large-scale investigations, including National Institute of Health- and American Diabetes Association (ADA)-sponsored studies. His current research interests include developing new drugs to treat and prevent diabetes and its complications, and understanding the role of the fat cell in increasing the risk for diabetes and heart disease. Professor Pratley has published and lectured extensively, has written numerous chapters on the aetiology and management of type 2 diabetes, and serves as a member of the editorial boards of Diabetes Care, Coronary Artery Disease and Current Diabetes Reports.</td></tr></table>",
//Array 13 =  Lena Landstedt-Hallin
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Lena Landstedt-Hallin</strong><br><i>Stockholm, Sweden </i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/novonordisk/Hallin.jpg'></td><td>Lena Landstedt-Hallin has been a Consultant in Endocrinology and Diabetology at Danderyd University Hospital since 1997. She studied Mathematics at Mt. Holyoke College, Massachusetts, USA, before further study for an MD at the Karolinska Institute (KI), Stockholm. She completed Residencies in both Internal Medicine and Endocrinology/Diabetology while studying for a PhD at KI and she presented her thesis in 2000. During the past 20 years Dr Landstedt-Hallin has seen many diabetes patients in her clinical work, combining this with research and administrative position in the hospital. She has acted as an investigator in both local and multicentre studies, from which results have been published in Diabetes Care and Diabetic Medicine and she was the Principal Investigator for the PREDICTIVE<sup>TM</sup> Study in Sweden. In addition to her clinical work, Dr Landstedt-Hallin acts as a supervisor for a PhD student and teaches clinical skills to medical students at KI.</td></tr></table>",
//Array 14 =  Michael Pollak
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Michael Pollak</strong><br><i>Montr&eacute;al, Canada </i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/novonordisk/Pollak.jpg'></td><td>Michael Pollak is Professor in the Departments of Medicine and Oncology at McGill University in Montreal. He is a medical oncologist with a clinical interest in hormone-dependent cancers. Dr Pollak's laboratory research emphasises roles of insulin, insulin-like growth factors (IGFs), and energy balance in neoplasia. He has contributed to efforts to develop and evaluate new drugs that attenuate the stimulatory effect of insulin and IGFs on cancer cells. He also manages a reference lab for measuring serum levels for peptide hormones to support epidemiologic research. He has received funding support from major Canadian and US agencies on an ongoing basis for more than 20 years, and has authored more than 250 publications.</td></tr></table>",
//Array 15 =  Lois Jovanovic 
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Lois Jovanovi&#269; </strong><br><i>Santa Barbara, CA, USA </i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/novonordisk/Jovanovic.jpg'></td><td>CEO & Chief Scientific Officer, Sansum Diabetes Research Institute<br>Clinical Professor of Medicine, University of Southern California-Keck School of Medicine<br>Adjunct Professor of Biomolecular Science and Engineering and Chemical Engineering, University of California-Santa Barbara<br><br>Lois Jovanovi&#269;, M.D., MACE, a specialist in endocrinology and metabolism has dedicated her life to diabetes research. Through her research, she established the Diabetes and Pregnancy Program and protocols of intensive insulin delivery which have become the standard of care for all pregnant women with diabetes. In addition, her work in the field of intensified insulin management and glucose monitoring for people with diabetes has led to the development of an artificial pancreas. Dr Jovanovi&#269;, an extraordinary teacher and mentor to aspiring physicians, has authored over 500 books and scientific articles. She is an internationally acclaimed speaker invited to present her research at congresses throughout the world.</td></tr></table>",
//Array 16 =  Dr. Copeland
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Kenneth Copeland</strong><br><i>Oklahoma City, OK, USA</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/novonordisk/Copeland.jpg'></td><td>Kenneth Copeland is the Jonas Chair and Chief of Pediatric Diabetes/Endocrinology at the University of Oklahoma Health Sciences Center. He graduated from Baylor University and Baylor College of Medicine, with residency in Paediatrics at Vanderbilt University, and completed Pediatric Endocrinology fellowships at the University of Geneva and the University of North Carolina. He held faculty positions at the University of Texas Medical School in San Antonio, the University of Vermont, and Baylor College of Medicine. His research focuses on pubertal growth and diabetes, and he has published approximately 120 scientific papers, chapters, and editorials, including the first published national standards for care of children with type 1 diabetes. He is a former Associate Editor of Diabetes Care, and the national study co-Chair of the NIH-funded TODAY trial. In May, 2007 he completed his term as President of the Lawson Wilkins Pediatric Endocrine Society, the national society of paediatric endocrinologists.</td></tr></table>",
//Array 17 =  Vivian A. Fonseca
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Vivian A. Fonseca</strong><br><i>New Orleans, LA, USA</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/novonordisk/Fonseca.jpg'></td><td>Vivian A. Fonseca, MD, FRCP, is Professor of Medicine, Tullis-Tulane Alumni Chair in Diabetes, and chief of the Section of Endocrinology, Tulane University Medical Center in New Orleans. He is currently Vice President, Science and Medicine of the American Diabetes Association. He has been Editor in Chief of Diabetes Care since 2007, and has served on the clinical practice committee of the American Diabetes Association and the joint ADA/ACC &rdquo;Make the Link&ldquo; Program. Dr Fonseca is a fellow of the American Association of Clinical Endocrinologists, the Royal College of Physicians (London), and the American College of Physicians. He is a member of the Endocrine Society, the American Diabetes Association, and the International Diabetes Federation. He has published over 200 papers, review articles and book chapters, and is the editor of &rdquo;Clinical Diabetes: Translating Research into Practice&ldquo; (Elsevier 2006). His research interests include prevention and treatment of diabetic complications and risk factor reduction in cardiovascular disease.</td></tr></table>",
//Array 18 =  Tim Heise
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Tim Heise</strong><br><i>Neuss, Germany</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/novonordisk/Heise.jpg'></td><td>Tim Heise is CEO of the private research institute, Profil Institute for Metabolic Research in Neuss. Dr Heise has led numerous early and later phase studies concerning insulin resistance, hypertension, obesity, antidiabetic drugs and insulin administration forms, as well as pharmacokinetic and pharmacodynamic properties of novel insulin preparations. In addition, his study team at Profil has gained an outstanding reputation for the evaluation of medical devices, in particular non-invasive and minimally invasive glucose sensors. Before establishing Profil, Dr Heise worked for more than seven years at the clinic for nutrition and metabolic diseases at the Heinrich-Heine-University D&uuml;sseldorf. In addition to his clinical work, Dr Heise has published more than 80 scientific papers and reviews on the characteristics of novel insulins, but also on the topic of insulin sensitivity, treatment of type 2 diabetes, hypertension and diabetic nephropathy. He is co-founder of DIeM, the Institute for Evidence-based Medicine in Cologne.</td></tr></table>",

// Ab hier Speaker GlaxoSmithKline

//Array 19 =  Johnny Ludvigsson
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Johnny Ludvigsson</strong><br><i>Department of Paediatrics<br>Link&ouml;ping University<br>Link&ouml;ping, Sweden</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/gsk/Ludvigsson.jpg'></td><td>Johnny Ludvigsson is currently Professor of Pediatrics in the Department of Pediatrics and Chairman of the Diabetes Research Centre, Link&ouml;ping University, Link&ouml;ping, Sweden. He has held positions within the department since 1977 and has been Professor since 1985.<br><br>Professor Ludvigsson was awarded his MD from Uppsala University, Sweden in 1969 and a PhD in 1976 on metabolic control in juvenile diabetes mellitus. In 1989, Professor Ludvigsson founded the Swedish Child Diabetes Foundation, of which he remains its chairman. He has received many awards including the first ever International Society for Pediatric Adolescent Diabetes award in 2001 for 'outstanding research in childhood diabetes'.<br><br>Professor Ludvigsson is the principal investigator for several large clinical trials and the national coordinator for several international studies in diabetes. He performed the world's first immune intervention at onset of type 1 diabetes (T1D) in children (plasmapheresis) which as a side effect lead to the discovery of 64kD, later shown to be glutamic acid decarboxylase (GAD), and in 1994 demonstrated the best results at the time for the prevention of diabetic nephropathy. He is currently investigating the role of GAD for preservation of residual insulin secretion in children with recent onset T1D and is planning a prevention of T1D trial including high-risk children from the large ABIS study. Professor Ludvigsson has authored more than 300 articles in peer-reviewed journals and has authored many other book chapters and abstracts. He is regularly invited to speak at international congresses and has also chaired many congresses and symposia.</td></tr></table>",
//Array 20 =  Andrew Morris
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Andrew Morris</strong><br><i>Biomedical Research Institute<br>University of Dundee<br>Dundee, UK</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/gsk/Morris.jpg'></td><td>Andrew Morris is Professor of Diabetic Medicine and Director of the Biomedical Research Institute at the University of Dundee. He leads a translational research team that focuses on the epidemiological and molecular aetiological basis of diabetes and its complications. He also has a major interest in how managed clinical networks can improve patient care across geographical boundaries. He leads the internationally acclaimed DARTS research study, has published over 200 original papers and has attracted over &pound;20m in peer-reviewed grant funding. He is the principal investigator on many clinical studies of new therapeutics of diabetes as well as genetics of diabetes, including the Wellcome Trust United Kingdom Case Control Collection for Type 2 Diabetes that is recruiting 15,000 individuals. He is also principal investigator of Generation Scotland, a study of the genetic health in 50,000 Scots. He was awarded the RD Lawrence Award by Diabetes UK in 2003, the Saltire Society Scottish Science Award in 2005 and is a Fellow of the Royal Society of Edinburgh, Scotland's national academy of science and letters, Fellow of the Academy of Medical Sciences and a Governor of the Health Foundation. He was appointed by the Minister for Health and Community Care to be Lead Clinician for diabetes in Scotland (2002-2006) and led a national programme of quality improvement in diabetes care. He also chairs the Translational Medicine Research Collaboration Steering Group, a unique &pound;50m collaboration between all medical schools in Scotland and the pharmaceutical company Pfizer.</td></tr></table>",
//Array 21 =  Stephanie A Amiel
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Stephanie A Amiel</strong><br><i>King's College London<br>London, UK</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/gsk/Amiel.jpg'></td><td>Stephanie A Amiel is the RD Lawrence Professor of Diabetic Medicine at King's College London and consultant diabetologist at King's College Hospital (KCH). She trained at Guy's Hospital with Harry Keen and started her academic career at Yale, with Robert Sherwin and Bill Tamborlane. With the Yale group, she described the physiological insulin resistance of healthy and diabetic puberty; and the failure of counterregulation that underlies hypoglycaemia unawareness and high risk of severe hypoglycaemia in diabetes patients.<br><br>Professor Amiel now leads a metabolic neuroimaging research group with neuroimaging colleagues at King's. She has described the cortical responses to hypoglycaemia in hypoglycaemia unawareness and has also described insulin sensitivity of the human appetite and satiety centres, with a detrimental effect of insulin resistance and type 2 diabetes on these centres' responses to food and food cues.<br><br>Clinically, Professor Amiel runs a service for pregnancy in diabetes with obstetric colleagues and a large intensive diabetes service which provides the type 1 patient education programme in flexible insulin therapy, Dose Adjustment for Normal Eating (DAFNE, which she pioneered in the UK with colleagues from King's, Sheffield and North Tyneside) and also serves over 200 patients on insulin pumps. She started the King's human islet isolation and clinical transplant programme in collaboration with the KCH Liver Transplant Service - islet transplantation is now available in the UK for the treatment of intractable hypoglycaemia in diabetes patients under the National Health Service.  Most recently, she has set up the South London Diabetes Study (SOUL-D) with collaborators Khalida Ismail and others, recruiting incident cases of type 2 diabetes in a longitudinal cohort study of the impact of psychosocial factors on diabetes outcomes. Professor Amiel teaches undergraduate and graduate students in diabetes and serves on the research committees of Diabetes UK, the Juvenile Diabetes Research Foundation International and the European Federation for the Study of Diabetes. </td></tr></table>",
//Array 22 =  Mark Peakman
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Mark Peakman</strong><br><i>Department of Immunobiology<br>King's College London<br>London, UK</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/gsk/Peakman.jpg'></td><td>Mark Peakman trained in medicine at University College Hospital and pursued postgraduate training in clinical immunology. After he received his PhD in immunology of type 1 diabetes (T1D) he held a senior clinical research fellowship at the University of Pittsburgh. He subsequently returned to the UK and now oversees a research group at King's College London in the Department of Immunobiology. The main focus of the research is the role of T lymphocytes in the aetiology of T1D, an autoimmune disease. In particular, the group has defined critical targets for autoreactive CD4 and CD8 T cells that appear to have a role in the destruction of beta cells, and key immunological pathways through which this damage is mediated. More recently, the group has used the definition of beta cell targets to design an approach to immunotherapy that utilises the antigen-specific approach. The group's studies on peptide immunotherapy were the first of their kind in T1D, and further phases of this programme are ongoing. In the future, a better understanding of the role of the immune response in T1D will promote the development of novel therapeutic strategies that aim to restore immunological tolerance.</td></tr></table>",
//Array 23=  Bart Keymeulen
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Bart Keymeulen</strong><br><i>Diabetes Research Center<br>Brussels Free University<br>Brussels, Belgium</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/gsk/Keymeulen.jpg'></td><td>Bart Keymeulen is currently Head of the clinical trial section of the Juvenile Diabetes Research Foundation Center for Beta Cell Therapy in Diabetes at the Diabetes Research Center, Brussels, Belgium. In addition, he is Senior Investigator at the Belgian Scientific Research Fund, Flanders, Belgium, Head of the Department of Diabetology of University Hospital UZ Brussel and Professor of Medicine at Brussels Free University.<br><br>Professor Keymeulen carried out his medical studies at Brussels Free University from 1978 to 1985, subsequently gaining a PhD in Medical Sciences. His current research interests focus on the development of beta-cell therapy in human type 1 diabetes. Major accomplishments include a trial on the prevention of decline of beta-cell function in recent-onset type 1 diabetic patients and an islet beta-cell transplantation study in non-uremic patients that was based on earlier observations in type 1 diabetic patients with a prior kidney graft.<br><br>He is a member of many national and international societies including the Belgian Transplantation Society, the European Association for the Study of Diabetes and the American Diabetes Association. He is the recipient of several awards, most recently the Prize of the Belgian Royal Academy of Medicine. He is the author of 64 publications in peer-reviewed journals, mostly in the field of type 1 diabetes and is invited regularly to speak at, and chair, many national and international congresses and symposia.  </td></tr></table>",

//Ab hier Speaker Novartis
//Array 24=  Roy Taylor
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Roy Taylor</strong><br><i>Newcastle University, UK</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/novartis/Taylor.jpg'></td><td>Roy Taylor is Professor of Medicine and Metabolism at Newcastle University in the UK and honorary consultant physician at the Royal Victoria Infirmary in Newcastle. He is also Director of the Newcastle Magnetic Resonance Centre, a new facility to further the medical and scientific knowledge of human physiology through in vivo study. Major current magnetic resonance-based research concerns the pathophysiological basis of type 2 diabetes.<br><br>His other recent research activities include: the management of incidental hyperglycaemia in acute medical emergencies; the effect of oral hypoglycaemic agents on postprandial control of hepatic glucose production; direct assessment of muscle glycogen and lipid storage after meals; and the long-term progression of retinopathy. He has also demonstrated the abolition of avoidable blindness in working-age people with diabetes by use of a district-wide retinal screening programme.<br><br>Professor Taylor has authored over 190 original papers and reviews and has given over 60 invited lectures at institutions worldwide. He has received several honours and awards, including the Croom Lectureship of the Royal College of Physicians of Edinburgh, the RD Lawrence Lectureship of the British Diabetic Association, the Albert Renold Fellowship, the Samuel Leonard Simpson Fellowship, the Honyman-Gillespie Lecture and the Arnold Bloom Lecture.<br><br>Professor Taylor was awarded his medical degree at the University of Edinburgh in Scotland.</td></tr></table>",
//Array 25=  Emanuele Bosi
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Emanuele Bosi</strong><br><i>Vita-Salute San Raffaele University, Milan, Italy</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/novartis/Bosi.jpg'></td><td>Emanuele Bosi is currently Associate Professor of Endocrinology and Director of the Postgraduate School of Endocrinology and Metabolic Diseases at the Vita-Salute San Raffaele University, and Head of the Department of Internal Medicine at the San Raffaele Hospital Scientific Institute, Milan, Italy. He is also principal investigator and a member of the steering committee of the National Institutes of Health-sponsored Diabetes TrialNet study group and Director of the TrialNet Clinical Centre in Italy.<br><br>He graduated in medicine in 1979 from the University of Milan, Italy, where he also received a specialty diploma in diabetes and metabolic diseases and subsequently in clinical immunology. During his career he has received clinical training in Milan and worked as clinical investigator at the Edouard Herriot Hospital in Lyon, France, and University College and St Bartholomew's Hospitals in London, UK.<br><br>Professor Bosi's research activity has been entirely devoted to diabetes, with specific regard to the prediction and prevention of type 1 diabetes and innovative treatments of diabetes, including transplantation, immunotherapy, artificial devices and innovative drugs. He is a leader in clinical investigations and clinical trials on both type 1 and type 2 diabetes and diabetic complications, and has published over 100 scientific papers.</td></tr></table>",
//Array 26=  Chantal Mathieu
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Chantal Mathieu</strong><br><i>Catholic University of Leuven, Belgium</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/novartis/Mathieu.jpg'></td><td>Chantal Mathieu is Professor of Medicine and Programme Director of Biomedical Sciences at the Catholic University of Leuven, Belgium. She earned her MD at the Catholic University and trained there in internal medicine and endocrinology. Her PhD work was entitled 'Immune intervention in animal models of type I diabetes: pathogenetical and therapeutical aspects'.<br><br>Professor Mathieu has authored or co-authored over 200 articles in peer-reviewed journals, and is currently a member of the advisory board for Diabetologia. She is a member of the Research Council of the Catholic University of Leuven and of the Research Council of Flanders, and a member of the European Association for the Study of Diabetes, the American Diabetes Association and the Immunology of Diabetes Society. She is also former president of the Flemish Diabetes Association.<br><br>Professor Mathieu's main research interest is the prevention of type 1 diabetes and islet transplantation. Clinically she is responsible for the organisation of diabetes care in the University Hospital, UZ Gasthuisberg, and is involved in the organisation of clinical diabetes care on a national and international basis.</td></tr></table>",
//Array 27=  R&uuml;diger G&ouml;ke
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>R&uuml;diger G&ouml;ke</strong><br><i>Center for Diabetes and Endocrinology, Kirchhain/Marburg, Germany</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/novartis/Goke.jpg'></td><td>R&uuml;diger G&ouml;ke has been a practising internist, endocrinologist and diabetologist at the Center for Diabetes and Endocrinology, Kirchhain/Marburg, Germany since 2006. He graduated in medicine in 1985 from the University of G&ouml;ttingen, Germany, and was certified in internal medicine in 1995 and in endocrinology and diabetology in 2003.<br><br>Professor G&ouml;ke has worked in the Department of Clinical Biochemistry at the Rigshopitalet, University of Copenhagen, Denmark, and worked as a research associate at the Institute for Human Gene Therapy at the University of Pennsylvania, USA. In 2000 he became Associate Professor at the University of Marburg and Head of the Clinical Research Unit for Gastrointestinal Endocrinology at the Department of Gastroenterology, Endocrinology and Metabolism.<br><br>Professor G&ouml;ke has won numerous awards for his work, including the Asche and Thannhauser awards of the German Society for Gastrointestinal and Metabolic Diseases, and the Heisenberg grant from the German Science Foundation. He has published widely in the fields of endocrinology and diabetes.</td></tr></table>",
//Ab hier Speaker BMS AstraZeneca Vormittag
//Array 28=  Clifford J. Bailey
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Clifford J. Bailey</strong><br><i>Aston University, Birmingham, United Kingdom</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/BMS/Bailey.jpg'></td><td>Cliff Bailey is Head of Diabetes Research and Professor of Clinical Science at Aston University in Birmingham, United Kingdom. His research is mainly directed towards the pathogenesis and treatment of diabetes, especially the development of new agents to improve insulin action and reduce obesity, and the therapeutic application of surrogate beta-cells. Professor Bailey is presently editor of the British Journal of Diabetes and Vascular Disease and senior editor of Diabetes and Vascular Disease Research. He has served on the medical and scientific committee of Diabetes UK (formerly the British Diabetic Association) and was secretary during 1991-1994. He has also served on the Society for Endocrinology programme committee and he was a founder member of the European Association for the Study of Diabetes Islet Study Group.</td></tr></table>",
//Array 29=  Krzysztof Strojek
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Krzysztof Strojek</strong><br><i>Silesian Medical University, Zabrze, Poland</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/BMS/Strojek.jpg'></td><td>Krzysztof Strojek is Head of Diabetological Unit in Department of Internal Diseases, Diabetology and Nephrology in Zabrze, Poland. He is also the Head of Regional Out-Patient Clinic for Diabetics. Professor Strojek's scientific interests are connected with diabetology; he is mainly interested in the pathogenesis and genetics of late complications and optimal therapy in diabetes. He is currently a Member of the Board of the Polish Diabetological Association. Previously, he has been a Member of the Council of the European Association for the Study of Diabetes during 2000-2003 and Vice President of the Hypertension in Diabetes EASD Study Group during 1999-2002.</td></tr></table>",
//Array 30=  Michael Nauck
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Michael Nauck</strong><br><i>Diabeteszentrum Bad Lauterberg, Harz, Germany</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/BMS/Nauck.jpg'></td><td>Since May 2000, Michael Nauck has been Head of the Diabeteszentrum Bad Lauterberg, Harz, Germany. Professor Nauck maintains an active clinical practice as well as a productive research programme. His areas of scientific interest include the role and impact of gastrointestinal peptide hormones for the physiological stimulation of insulin secretion. He has contributed to the development of new therapeutic principles for the treatment of type 2 diabetes based on antidiabetic properties of gut hormones and of other glucagon-like peptide-1 (GLP-1) receptor agonists. Professor Nauck is editor of Diabetes Newsletter and associate editor of Diabetes. He is a member of Deutsche Diabetes-Gesellschaft, European Association for the Study of Diabetes (EASD), American Diabetes Association (ADA), International Diabetes Federation (IDF) and American Physiological Society (APS).</td></tr></table>",
// Ab hier Speakers RESMED
//Array 31=  Professor Sir George Alberti 
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Professor Sir George Alberti </strong><br><i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/resmed/Alberti.jpg'></td><td>Professor Sir George Alberti is Chair of Diabetes UK, Senior Research Fellow at Imperial College and Emeritus Professor of Medicine at the University of Newcastle. He is also Clinical Adviser on Service Transformation for NHS London. Sir George has been President of the Royal College of Physicians (London), President of the International Diabetes Federation and of The European Association for the Study of Diabetes. He works extensively with the World Health Organization. He has been heavily involved in diabetes work in sub-Saharan Africa, particularly Tanzania, and in Mauritius. He has published more than 1,100 articles on diabetes and metabolism. </td></tr></table>",
//Array 32=  Allan Flyvbjerg 
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Allan Flyvbjerg</strong><br><i>Department of Endocrinology and Internal Medicine, Aarhus University Hospital and Clinical Institute of Medicine, University of Aarhus, Denmark </i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/resmed/Flyvbjerg.jpg'></td><td>Professor Allan Flyvbjerg graduated from Aarhus University, Denmark in 1986, he defended his thesis (DMSc) in 1993, became specialist in Internal Medicine and Endocrinology in 1999, Chief Physician in 2001, Professor in Experimental Medical Research in 2005 and Clinical Professor of Endocrinology (Chair) in 2009.  Allan Flyvbjerg and his research team perform preclinical and clinical research focused on the pathogenesis leading to diabetic micro- and macroangiopathy. The aim of the research is to combat the increased incidence and prevalence of cardiovascular disease, blindness and end-stage renal failure in patients with diabetes. He is author of more than 475 scientific publications and well cited with a H-index well above 40.  Allan Flyvbjerg has been President of the Danish Diabetes Association (app. 80.000 members) since 2000 and is member of several national and international boards and councils. He has been Associate Editor of Diabetologia since 2007 and has been awarded prestigious Prizes for his research in diabetes, including the EASD Castelli Pedroli Prize / 16th Camillo Golgi Lecture in 2001, the ESCI Award for Excellence in Clinical Science in 2004, the Christian Hagedorn Award in 2006, the SSSD Knud Lundb&aelig;k Award in 2007, the Dorothy Hodgkin Prize awarded by Diabetes UK in 2009, the Majesty Queen Ingrid Celebration Lecture in 2010 and the Ruth &Oslash;sterby Prize awarded by the European Diabetic Nephropathy Study Group (EDNSG) 2010. </td></tr></table>",
//Array 33=  Professor Martin Cowie  MD MSc FRCP FESC 
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Professor Martin Cowie  MD MSc FRCP FESC </strong><br><i>National Heart & Lung Institute, Imperial College, London, UK; & Royal Brompton Hospital, London, UK</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/resmed/cowie.jpg'></td><td>Professor Martin Cowie is Professor of Cardiology at the National Heart & Lung Institute, Imperial College, London, UK and Honorary Consultant Cardiologist at the Royal Brompton Hospital, London. A founding member and chairman of the British Society for Heart Failure, Professor Cowie has also been a Board member (and Chair of the Education Committee) of the Heart Failure Association of the European Society of Cardiology (ESC). He advises the National Institute for Clinical Excellence (NICE) on the management of chronic heart failure, and the Quality Care Commission on its heart failure audit work. <br><br>Professor Cowie's studies and reviews have been featured in a variety of peer-reviewed journals, including The Lancet, European Heart Journal, British Medical Journal, Heart, European Journal of Heart Failure, J American College of Cardiology  and Journal of Cardiac Failure. He is a member of the editorial board of Heart, The British Journal of Diabetes and Vascular Diseases, and Cardiovascular Diabetology. He has contributed chapters to many books, and has written a book for patients entitled 'Living with Heart Failure &ndash; a guide for patients'.<br><br>He is the cardiological principal investigator for the SERVE-HF Study &ndash; a multicentre international randomised trial of servo-assisted ventilation in patients with systolic heart failure and predominantly central sleep disordered breathing. </td></tr></table>",
//Array 34=  Søren Berg 
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>S&oslash;ren Berg </strong><br><i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/resmed/berg.jpg'></td><td>Medical degree from University of Copenhagen, Denmark 1984<br>Qualification as a specialist in Ear-, Nose- and Throat 1990 <br>Doctoral dissertation in medicine at the University of Lund, Sweden 1997 <br>Co-founder of ScanSleep 2000 <br>Associate professor at the University of Lund 2007 </td></tr></table>",
//Array 35=  Pr Antoine Avignon, MD, PhD 
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Prof Antoine Avignon, MD, PhD </strong><br><i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/resmed/avignon.jpg'></td><td>Professor Antoine Avignon is a professor of Nutrition at the University of Montpellier 1, Medical School since 1999. He currently leads the team of Diabetology-Nutrition at the University Hospital of Montpellier. His research focuses on the complications of diabetes and the relationship between diet and insulin resistance. He has published several international articles in these areas.</td></tr></table>",

// Ab hier Speaker Boehringer Ingelheim
//Array 36=  Julio Rosenstock, MD
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Julio Rosenstock, MD</strong><br><i>Dallas Diabetes and Endocrine Center and University of Texas Southwestern Medical Center, Dallas,Texas, USA</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/Boehringer-Ingelheim/Rosenstock.jpg'></td><td>Dr. Julio Rosenstock is Director of the Dallas Diabetes and Endocrine Center, an endocrine practice and clinical research facility, and Clinical Professor of Medicine at the University of Texas Southwestern Medical Center. He is actively involved in diabetes education and serves as the Endocrine Society representative to the National Diabetes Education Program. His clinical and research activities have focused on exploring novel agents and therapeutic strategies to improve glycemic control, particularly early insulin intervention with combination strategies in type 2 diabetes. He also has a special interest in DPP-4 inhibitors and GLP-1 receptor agonists and acts as a clinical investigator and scientific advisor. He has authored 280 publications including peer-reviewed manuscripts, abstracts, clinical reviews and book chapters. He is currently an editorial board member of Diabetes Care, Practical Diabetology, Cardiovascular Diabetology and Avances en Diabetologia and is an active reviewer for several journals.</td></tr></table>",
//Array 37=  Professor Michael Nauck, MD PhD
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Professor Michael Nauck, MD PhD</strong><br><i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/Boehringer-Ingelheim/Nauck.jpg'></td><td>Since 2000, Professor Michael Nauck has been head of the Diabeteszentrum Bad Lauterberg, Germany, which is a specialist hospital for the care and therapy of patients with diabetes mellitus and other metabolic disorders. In addition to active membership of numerous professional societies, Professor Nauck has the honour of being the Programme Chair for this year's annual meeting of the German Society for the Study of Diabetes, to be held in Stuttgart, Germany, in May.<br><br>Professor Nauck's research interests include investigation of the role of gastrointestinal peptide hormones in stimulation of insulin secretion, aspects of heart disease in diabetic patients, the metabolic consequences of pancreas transplantation and the development of diagnostic tests for spontaneous hypoglycaemia (insulinomas and other conditions). He has authored over 200 original papers and reviews and 28 book chapters. Professor Nauck has been an associate editor of Diabetes since July 2006 and is a reviewer for over 25 other journals, including the American Journal of Physiology, the European Journal of Clinical Investigation, Life Sciences and Nature Clinical Practice (Endocrinology and Metabolism). </td></tr></table>",
//Array 38=  Professor Antonio Ceriello, MD
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Professor Antonio Ceriello, MD</strong><br><i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/Boehringer-Ingelheim/Ceriello.jpg'></td><td>Antonio Ceriello is Professor at the Institut d'Investigacions Biom&egrave;diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Professor Ceriello has published widely in the area of diabetes with over 200 original papers and several book chapters. He has been consultant to the National Institutes of Health, USA, for their cardiovascular disease and type 1 diabetes research programmes between 2003-2005, and a member of the Writing Committee of the American Heart Association guidelines on Acute Hyperglycemia and Acute Coronary Syndromes. He has recently chaired the International Diabetes Federation (IDF) Committee for the development of Guidelines for Management of Post Meal Glucose and he is currently the President of the European Association for the Study of Diabetes (EASD) Study Group on Diabetes and Cardiovascular Diseases and a Member of the Board of the IDF Europe. He is also currently serving as Associate Editor of Diabetes Care and Diabetic Medicine. Professor Ceriello is the winner of the 2004 Castelli Pedroli Prize from the EASD. </td></tr></table>",
//Array 39=  Professor Steven E Kahn, MB, ChB
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Professor Steven E Kahn, MB, ChB</strong><br><i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/Boehringer-Ingelheim/Kahn.jpg'></td><td>Dr Kahn is a Professor of Medicine in the Division of Metabolism, Endocrinology, and Nutrition at the VA Puget Sound Health Care System and University of Washington in Seattle, USA. Additionally, he is Associate Director of the Diabetes Endocrinology Research Center at the University of Washington.<br><br>Dr Kahn's research interests include &beta;-cell function in normal subjects and the pathogenesis of hyperglycaemia in patients with type 2 diabetes. He has also done extensive work on the role of islet amyloid in the pathogenesis of the islet lesion in type 2 diabetes.<br><br>Among his awards are the Herman Ostrum Memorial Award, the Dana Foundation Feasibility Award, the Novartis Award in Diabetes, the American Diabetes Association Distinguished Clinical Scientist Award, and the R H Williams-Rachmiel Levine Award. He has been elected to membership in the American Society for Clinical Investigation and the American Association of Physicians.</td></tr></table>",
//Array 40=  Professor Per-Henrik Groop, MD, DMSc
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Professor Per-Henrik Groop, MD, DMSc</strong><br><i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/Boehringer-Ingelheim/Groop.jpg'></td><td>Professor Per-Henrik Groop is a specialist in diabetes and nephrology. He is currently Head of the Department of Diabetes Genetics at Folkh&auml;lsan Research Center in Helsinki, Finland, and Deputy Chief Physician in the Department of Medicine at Helsinki University Central Hospital. His main work is focused on dissection of the pathogenesis of diabetic complications with special emphasis on diabetic nephropathy. In 1997, Professor Groop initiated FinnDiane, the large, nationwide Finnish Diabetic Nephropathy Study. This study includes 5,000 patients with type 1 diabetes and their family members who were recruited via a network of 92 hospitals and healthcare centres throughout Finland, and covers 16% of all patients in Finland with type 1 diabetes. Professor Groop was Associate Editor of Diabetologia between 2005-2007, and is currently Associate Editor of Kidney International and International Diabetes Monitor. He is President of the European Diabetic Nephropathy Study Group. In 2009, Professor Groop received the prestigious Castelli-Pedroli Prize at the EASD in Vienna, Austria, in 2009.</td></tr></table>",
//Array 41=  Professor Ele Ferrannini, MD
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Professor Ele Ferrannini, MD</strong><br><i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/Boehringer-Ingelheim/Ferrannini.jpg'></td><td>Ele Ferrannini is the Professor of Medicine in the Department of Internal Medicine, University of Pisa School of Medicine, and Chief of the Metabolism Unit of the CNR (National Research Council) Institute of Clinical Physiology at the University of Pisa, Pisa, Italy. He also holds the position of Adjunct Clinical Professor of Medicine, Diabetes Division, University of Texas Health Science Center at San Antonio, Texas, USA.<br><br>Professor Ferrannini is listed as one of the most highly cited scientists (www.ISIHighlyCited.com), having been involved in over 450 publications in the fields of diabetes, metabolism, hypertension, obesity and cardiovascular risk factors. He is Chairman of the European Group for the Study of Insulin Resistance and Past-President of the European Association for the Study of Diabetes (2004-2008). He was formerly Editor-in-Chief of Diabetologia, the official journal of the European Association for the Study of Diabetes, and Co-Editor of the International Textbook of Diabetes Mellitus (3rd Edition).</td></tr></table>",
//Array 42=  Bo Ahrén
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Bo Ahr&eacute;n</strong><br><i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/msd/Ahren.jpg'></td><td>Bo Ahr&eacute;n received his MD at Lund University in 1977. He became associate professor at Lund University in 1981 and professor in Clinical Metabolic Research at Lund University in 1999. He is clinically a consultant at the Department of Endocrinology at Lund University Hospital. He was the Chief Physician at the County of Sk&aring;ne 2004-2005 and he is since 2006 the Dean of the Faculty of Medicine, Lund University. <br><br>Dr Ahr&eacute;n has published >600 original articles and review articles within the area of insulin secretion. Dr Ahr&eacute;n has combined basic science with clinically oriented research to focus on this insulin secretion, with the special aim to understand the regulation and mechanism of normal insulin secretion and the mechanisms and consequences of failing insulin secretion as an important pathogenetic factor in diabetes. Dr Ahr&eacute;n has also worked to develop new targets and compounds for the treatment of type 2 diabetes. In this area, Dr Ahr&eacute;n has during recent years concentrated on incretin actions with particular emphases on developing new treatment for type 2 diabetes based on the incretin hormone GLP-1 and its inactivation enzyme, dipeptidyl peptidase-4 (DPP-4).</td></tr></table>",
//Array 43=  Lawrence A Leiter
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Lawrence A Leiter</strong><br><i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/msd/Leiter.jpg'></td><td>Dr. Lawrence A. Leiter is Head of the Division of Endocrinology and Metabolism, Director of the Lipid Clinic, and Associate Director of the Clinical Nutrition and Risk Factor Modification Centre at St. Michael's Hospital in Toronto. He is also a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.<br><br>Dr. Leiter has several research interests including clinical trials on the prevention of atherosclerosis, especially in diabetes, and the dietary and pharmacologic treatment of diabetes mellitus, hyperlipidemia, hypertension, and obesity. He has held research funding from various agencies including the NIH, CIHR/MRC and Canadian Diabetes Association and has over 370 publications in peer reviewed journals. He was an investigator in many of the landmark diabetes trials including the DCCT, ACCORD, and ADVANCE and is on the Steering Committees of many ongoing outcome trials in both the diabetes and lipid areas. <br><br>Dr. Leiter has been involved in many national and international committees and consensus conferences. He is the President-Elect of the Canadian Society of Endocrinology & Metabolism. He has also been actively involved in the Canadian Diabetes Association for many years and is a past Chair of its Clinical and Scientific Section. He was Co-Chair of the Canadian Diabetes Association Committee to revise the Clinical Practice Guidelines for the Management of Diabetes in Canada published in 1998 and was on the Steering Committee and Chair of the Macrovascular section for both the 2003 and 2008 revisions. He has also been involved in guidelines committees for the Canadian Hypertension Society and Obesity Canada. He was Co-chair of the 7th International Congress on Obesity which was held in Toronto in August 1994. <br><br>For his work, Professor Leiter has received a number of awards including the Canadian Diabetes Association Frederick G. Banting Award and the American Diabetes Association Charles H Best Award (awarded to DCCT investigators), both for Distinguished Service, the 2005 Canadian Society of Endocrinology and Metabolism Educator of the Year Award, and the 2006 Canadian Diabetes Association Gerald S. Wong Award in recognition of significant contribution to the diabetes community.</td></tr></table>",
//Array 44 = Prof Christian Berne (Sanofi)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Prof Christian Berne MD</strong> <br> <i>Uppsala University Hospital, Uppsala, Sweden</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/sanofi-aventis/Berne.jpg'></td><td>Christian Berne is Professor of Medicine, Department of Medical Sciences, Uppsala University, Uppsala, Sweden and Consultant Physician at the Division of Endocrinology and Diabetes, Uppsala University Hospital. He is a specialist in internal medicine and endocrinology. Prof. Berne has published over 200 papers in peer-reviewed journals and numerous reviews, book chapters and other publications covering both experimental and clinical diabetes research. He was a member of the European IDDM and NIDDM policy groups in 1993 and 1998 and the Hypertension in NIDDM Guidelines group in 1997 and 2001 (IDF-WHO). Prof. Berne acts as a Medical Advisor for the Swedish guidelines for diabetes care and is a member of the Professional Advisory Board of the Swedish Medical Products Agency. He was a member of the Organising Committee of the EASD meeting in Stockholm in 1995 and is a member of the Local Organising Committee of this year's meeting.</td></tr></table>",
//Array 45 = Matthew C. Riddle, MD (Sanofi)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Matthew C. Riddle, MD</strong> <br> <i>Oregon Health & Science University, Oregon, USA</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/sanofi-aventis/Riddle.jpg'></td><td>Dr. Riddle is Professor of Medicine at the Oregon Health & Science University, Oregon, USA. His interests include the physiology and treatment of T2DM, newer therapeutic agents, randomized clinical trials, and the organization of care for diabetes. He has published 148 articles, and has served on the Editorial Boards of Diabetes Care, Diabetes Technology & Therapeutics, and the Journal of Clinical Endocrinology &amp; Metabolism. Among other activities in clinical research, he currently has leadership responsibilities in several large international trials, including ACCORD, ORIGIN, and TIDE, all of which are testing the effects of treatments on cardiovascular and other medical outcomes in T2DM. In 2005, Dr. Riddle received the ADA Outstanding Physician Clinician Award. </td></tr></table>",
//Array 46 = Richard M. Bergenstal, MD (Sanofi)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Richard M. Bergenstal, MD</strong> <br> <i>International Diabetes Center, Minneapolis, USA</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/sanofi-aventis/Bergenstal.jpg'></td><td>Richard M. Bergenstal is an endocrinologist and Executive Director of the International Diabetes Center at Park Nicollet. He is Clinical Professor in the Department of Medicine at the University of Minnesota and serves as President, Science & Medicine of the ADA in 2010. In 2007, Dr. Bergenstal was named the ADA's Outstanding Physician Clinician of the Year and in 2010 he was awarded the Banting Medal for Service for outstanding leadership and service to the ADA. His clinical research has focused on glucose control and diabetes complications as a Principal Investigator of two NIH trials: the DCCT in T1DM and the ACCORD study in T2DM. He studies the effective utilization of insulin therapy and glucose monitoring (SMBG and CGM) to improve glucose control and clinical outcomes. He teaches nationally and internationally on the importance of patient-centered team care and has been listed in Best Doctors in America since it began in 1992. Dr. Bergenstal has published over 100 peer-reviewed scientific articles on diabetes and co-authored the best selling Betty Crocker Diabetes Cookbook. </td></tr></table>",
//Array 47 = Stefano Del Prato, MD (Sanofi)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Stefano Del Prato, MD</strong> <br> <i>University of Pisa, Pisa, Italy</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/sanofi-aventis/Del-Prato.jpg'></td><td>Dr. Del Prato is Professor of Endocrinology and Metabolism at the School of Medicine and Chief of the Section of Diabetes, University of Pisa, Italy. He also holds the post of Clinical Associate Professor of Medicine, University of Texas, San Antonio Health Science Center, Texas, USA. Dr. Del Prato's research interests have always been concerned with diabetes and in particular the physiopathology and therapy of type 2 diabetes and insulin resistance syndrome. He is a member of many societies and associations, including the EASD, the ADA and the IDF, and serves on the Editorial Boards of numerous journals including Acta Diabetologica, Diabetes & Vascular Disease Research, and the Journal of Clinical Endocrinology and Metabolism. Dr. Del Prato has published over 400 articles and has been awarded several honours, including the Prize of the Italian Society of Diabetology for outstanding scientific activity.</td></tr></table>",
//Array 48 = Satish K. Garg, MD, MBBS, DM (Sanofi)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Satish K. Garg, MD, MBBS, DM</strong> <br> <i>University of Colorado Health Sciences Center, Denver, USA</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/sanofi-aventis/Garg.jpg'></td><td>Satish Garg is Professor of Medicine and Pediatrics at the Young Adult Clinic of the Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Denver, Colorado. His research interests include the early detection and treatment of renal and retinal complications of diabetes, and the development of new diagnostic and therapeutic tools related to clinical diabetes management. Professor Garg is Editor-in-Chief of Diabetes Technology & Therapeutics and serves on the editorial boards of several international diabetes journals. He is a member of many medical associations, including the IDF, ADA, EASD, the Endocrine Society of India, and the Research Society for the Study of Diabetes Mellitus. Professor Garg has published many book chapters and more than 165 original manuscripts in peer-reviewed journals..</td></tr></table>",
//Array 49 = Satish K. Garg, MD, MBBS, DM (Sanofi)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Satish K. Garg, MD, MBBS, DM</strong> <br> <i>University of Colorado Health Sciences Center, Denver, USA</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/sanofi-aventis/Garg.jpg'></td><td>Satish Garg is Professor of Medicine and Pediatrics at the Young Adult Clinic of the Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Denver, Colorado. His research interests include the early detection and treatment of renal and retinal complications of diabetes, and the development of new diagnostic and therapeutic tools related to clinical diabetes management. Professor Garg is Editor-in-Chief of Diabetes Technology & Therapeutics and serves on the editorial boards of several international diabetes journals. He is a member of many medical associations, including the IDF, ADA, EASD, the Endocrine Society of India, and the Research Society for the Study of Diabetes Mellitus. Professor Garg has published many book chapters and more than 165 original manuscripts in peer-reviewed journals.</td></tr></table>",
//Array 50 = Thomas Danne, MD (Sanofi)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Thomas Danne, MD</strong> <br> <i>Hannover Medical School, Hannover, Germany</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/sanofi-aventis/Danne.jpg'></td><td>Prof. Dr. Thomas Danne is the Director of the Department of General Pediatrics and Endocrinology/Diabetology at the Kinderkrankenhaus auf der Bult, Hannover Medical School, Germany, and Head of the Diabetes Center for Children and Adolescents, which is the largest pediatric diabetes center in Germany. He is the current President of International Society for Pediatric and Adolescent Diabetes (ISPAD) and of the German Diabetes Association (DDG). His research interests include basic and clinical research in pediatric diabetology with special emphasis on new insulins, glucose sensors and insulin pumps. Prof. Danne is the Principal Investigator of several international multicentre studies, such as the recent pediatric ONSET trial and the European SWEET project, and is National Coordinator of the EU and NIH funded TRIGR-Study (Trial to Reduce IDDM in the Genetically at Risk).</td></tr></table>",
//Array 51 = Silva Arslanian, MD (Sanofi)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Silva Arslanian, MD</strong> <br> <i>Children's Hospital, Pittsburgh, USA</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/sanofi-aventis/Arslanian.jpg'></td><td>Professor Silva Arslanian is the Richard L. Day Endowed Professor of Pediatrics at the University of Pittsburgh School of Medicine. She is Director of the Pediatric Clinical and Translational Research Center at the Children's Hospital of Pittsburgh, and Director of the Weight Management &amp; Wellness Center. Her research interests include the pathophysiology of insulin resistance during childhood growth and development, metabolic syndrome, racial differences in insulin sensitivity and secretion, obesity, and type 2 diabetes in childhood. Professor Arslanian serves as a consultant to the National Institutes of Health, the Office of Human Research Protection, Centers for Disease Control, the ADA, the International Study of Pediatric and Adolescent Diabetes, the IDF, the European Medicines Agency, the German Federal Ministry of Education and Research, and the Dutch Medicines for Children Research Network (MCRN).</td></tr></table>",
//Array 52 = Bernard Zinman (Sanofi)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Bernard Zinman</strong> <br> <i>Mount Sinai Hospital, Toronto, Canada</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/sanofi-aventis/Zinman.jpg'></td><td>Bernard Zinman is Director of the Leadership Sinai Centre for Diabetes and holds the Chair in Diabetes Research at Mount Sinai Hospital and the University of Toronto, Canada. He is Professor of Medicine at the University of Toronto and Senior Scientist at the Samuel Lunenfeld Research Institute, Mount Sinai Hospital. Dr. Zinman is Principal Investigator of the University of Toronto Centre and Vice-Chair of the DCCT/EDIC study. His main research interests include the long-term complications of diabetes mellitus, the development of new therapies for T1DM and T2DM, diabetes in Aboriginal communities, and studies directed at the prevention of diabetes. Dr. Zinman has authored more than 350 publications in national and international journals, and over 60 book chapters and editorials. He is the recipient of numerous awards including the ADA's Outstanding Physician Clinician Award in 2006 and the Canadian Diabetes Association Lifetime Achievement Award in 2009.</td></tr></table>",
//Array 53 = Eric Renard (Sanofi)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Eric Renard</strong> <br> <i>CHU & University of Montpellier, Montpellier, France</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/sanofi-aventis/Renard.jpg'></td><td>Eric Renard is Professor of Endocrinology, Diabetes &amp; Metabolism at Montpellier Medical School, Montpellier 1 University, and Senior Medical Practitioner in the Department of Endocrinology, Diabetes and Nutrition, Lapeyronie University Hospital, Montpellier, France. He also holds the position of Medical Director of Clinical Research and Head of the INSERM Clinical Research Center at Montpellier University Hospital. Professor Renard's main field of clinical research is focused on intensive insulin therapy, the development of insulin pump therapy, and tools for continuous blood glucose monitoring. His current research involves participation in European Project DIAdvisor, European Project Bringing Artificial Pancreas at Home, and the JDRF-sponsored Artificial Pancreas Project. He has authored more than 120 papers in peer-reviewed journals.</td></tr></table>",
//Array 54 = Professor Dr Michael Roden (Lilly)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Professor Dr Michael Roden</strong> <br> <i>Heinrich-Heine University, D&uuml;sseldorf, Germany</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/Lilly/Roden.jpg'></td><td>Michael Roden is Endocrinologist, Professor of Medicine and Director of the Department of Metabolic Diseases at Heinrich-Heine University in D&uuml;sseldorf, Germany. He is also Scientific Director of the German Diabetes Center (DDZ), the Leibniz Center of Diabetes Research, D&uuml;sseldorf, Germany, and Director of the Karl-Landsteiner Institute for Endocrinology and Metabolism, Vienna, Austria. He has held positions as Head of the Department of Medicine at Hanusch Hospital, Teaching Hospital of Medical University of Vienna, Associate Professor of Medicine at Medical University of Vienna, and Max-Kade Fellow at Yale University, New Haven, Connecticut, USA. Dr Roden combined multitracer dilution techniques and multinuclear magnetic resonance spectroscopy to non-invasively assess metabolic pathways in humans. He contributed concepts to nutrient-induced insulin resistance and to energy metabolism in diabetic states, and was coordinator of the EU-funded, evidence-based guideline for diabetes prevention (IMAGE). <br><br>Dr Roden has published more than 200 papers in peer-reviewed journals and is continuously supported by the European Foundation for the Study of Diabetes (EFSD) and European Association for the Study of Diabetes (EASD) as well as national research foundations of Germany and Austria. He is on the editorial boards of Endocrinology, American Journal of Physiology, Journal of Molecular Medicine and European Journal of Clinical Investigation. Dr Roden is currently President of the Central European Diabetes Association (FID), as well as past Vice President of the European Society for Clinical Investigation (ESCI) and past President of the Austrian Diabetes Association. He has received several awards, including the International Novartis Award (2004), the ESCI-Award (2006) and the Oskar-Minkowski Prize by the EASD (2006).</td></tr></table>",
//Array 55 = Professor John Pickup, MA, BM, BCh, DPhil, FRCPath (Lilly)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Professor John Pickup, MA, BM, BCh, DPhil, FRCPath</strong> <br> <i>King's College London School of Medicine, Guy's Hospital, London, UK</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/Lilly/Pickup.jpg'></td><td>John Pickup is Professor of Diabetes and Metabolism at King's College London School of Medicine, Guy's Hospital, London, UK. He received both his PhD and medical training at the University of Oxford, UK. After a fellowship at the Massachusetts General Hospital, Boston, USA, and a postgraduate appointment at Hammersmith Hospital, London, he moved to Guy's Hospital in 1976.<br><br>Professor Pickup has a long-standing interest in the development and clinical application of novel technology for the improved management of diabetes, starting from the development of insulin pump therapy through to in vivo glucose sensors. His current research focuses on insulin pump therapy and continuous glucose monitoring in clinical practice, developing fluorescence approaches to glucose sensing, nanomedicine and diabetes, and activation of the innate immune system and inflammation as a cause of type 2 diabetes. He is the recipient of several research awards, including the R D Lawrence Lectureship of the British Diabetic Association (Diabetes UK), the Gotch Prize of Oxford University, the Boehringer Mannheim Fellowship of the Biochemical Society, the BUPA Foundation Research Award and the Diabetes Leadership Award of the Diabetes Technology Society.</td></tr></table>",
//Array 56 = Professor Simon Heller, BA, MB BChir, DM, FRCP (Lilly)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Professor Simon Heller, BA, MB BChir, DM, FRCP</strong> <br> <i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/Lilly/Heller.jpg'></td><td>Simon Heller is Professor of Clinical Diabetes at the University of Sheffield and Director of Research and Development and Honorary Consultant Physician at Sheffield Teaching Hospitals Foundation Trust, UK.  <br><br>He received his clinical diabetes training at Queen's Medical Centre, Nottingham, UK, and his research training at the University of Nottingham and Washington University, St Louis, USA before coming to Sheffield in 1990. From 2000-2005 he was Editor of Diabetic Medicine.<br><br>His current research interests include the physiological responses to hypoglycaemia and hypoglycaemia unawareness, pathophysiological mechanisms of sudden death in Type 1 Diabetes and developing interventions to encourage more effective diabetes self-management. He was a co-investigator, member of the Management Committee and Chair of the glucose control group in the ADVANCE study. </td></tr></table>",
//Array 57 = Professor Rémy Burcelin, PhD(Lilly)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Professor R&eacute;my Burcelin, PhD</strong> <br> <i>Rangueil Institute of Molecular Medicine, INSERM, France</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/Lilly/Burcelin.jpg'></td><td>R&eacute;my Burcelin is Research Director for l'Institut National de la Sant&eacute; et de la Recherche M&eacute;dicale (INSERM), where he is head of a team investigating the functional genomics of metabolic diseases at the Rangueil Institute of Molecular Medicine. Following the completion of his PhD in hormonal and metabolic regulation at the University of Paris in 1992, Professor Burcelin worked as a Post-Doctoral Fellow under Dr. M. J. Charron at the Albert Einstein College of Medicine in New York. He then held the post of Assistant Professor at the Lausanne University Institute of Pharmacology and Toxicology in Switzerland, before taking on his current role at INSERM, based in Toulouse, in 2001. Professor Burcelin is also a co-founder of the French CRO Physiogenex SAS, specialising in high-throughput analysis and screening of pharmacological and nutritional agents and molecular targets (including GLP-1) for the treatment of metabolic diseases. He currently serves as Chairman of its Scientific Advisory Board. <br><br>Professor Burcelin has authored many publications in the field of diabetes research and is a reviewer for several international medical journals, including Diabetes, the Journal of Clinical Investigation, the American Journal of Physiology, Gastroenterology and the British Journal of Nutrition. He has also been a member of the Editorial Board for Endocrinology since 2005 and President of the European club for the study of GLP-1 since 2008. Professor Burcelin is a member of several diabetes societies, including the Association de Langue Fran&ccedil;aise pour l'Etude du Diabete et des Maladies Metaboliques (ALFEDIAM), American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD). In 2003, he received the Appolinaire Bouchardat Award for his research in diabetes.</td></tr></table>",
//Array 58 = Anne Grapin-Botton(beta-cells)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Anne Grapin-Botton</strong> <br> <i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/beta-cells/Grapin-Botton.png'></td><td>Anne Grapin-Botton studied developmental biology of the nervous system in Paris (France) with Nicole Le Douarin and received her PhD in 1995. She carried out postdoctoral work with Doug Melton in Harvard University (Cambridge, USA) and joined ISREC (Swiss Institute for Experimental Cancer Research, Lausanne, Switzerland) as an associate scientist in 2001. In September 2005 she was appointed tenure track assistant professor in the School of Life Sciences at EPFL (Federal Polytechnic School of Lausanne).<br><br>She studies pancreas development and its implications in diabetes and pancreas cancer. Her experiments in mouse and chick embryos are designed to identify the signals and transcription factors  that control pancreas organogenesis during development with emphasis on endocrine cell differentiation. Her aim is to use this knowledge to promote pancreas regeneration and produce beta cells for replacement therapy. Her work relies heavily on imaging the developing pancreas and led her to develop, in collaboration with Pr T. Lasser's, group Optical Coherence Tomography to repeatedly image mouse islets in vivo in the pancreas.  </td></tr></table>",
//Array 59 = Anthony Barnett (BMS-AZ)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Anthony Barnett</strong> <br> <i>Clinical Director - Diabetes and Endocrinology, Heart of England NHS Foundation Trust</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/BMS/Barnett.jpg'></td><td>Anthony Barnett is Professor of Medicine, Consultant Physician and Clinical Director of Diabetes and Endocrinology at Heart of England NHS Foundation Trust which has one the largest Diabetes and Weight Management Units in the United Kingdom. He gained his medical degree from King's College, University of London. He subsequently trained at a number of hospitals and universities. For 2 years, he held the position of Medical Research Council Senior Fellow in Diabetes at King's College Hospital, London. He subsequently moved to Birmingham and is currently Professor of Medicine at the University of Birmingham. <br><br>Professor Barnett's research interests include the genetics of diabetes, the causes of complications of diabetes, the development of new therapies to treat diabetes and its long-term vascular complications and Health Service Related Research (including 'difficult to reach' groups). In addition to publishing over 400 original papers, he has written many books, review articles and editorials on diabetes, and has contributed chapters to major textbooks on the subject. He also regularly acts as adviser to NICE, the EMEA and the National Prescribing Centre on diabetes related therapies.</td></tr></table>",
//Array 60 = Stefano Del Prato (BMS-AZ)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Stefano Del Prato</strong> <br> <i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/BMS/DelPrato.jpg'></td><td>Stefano Del Prato is Professor of Endocrinology and Metabolism at the School of Medicine, University of Pisa and Chief of the Section of Diabetes, University of Pisa, Italy. He also holds the post of Clinical Associate Professor of Medicine, University of Texas, San Antonio Health Science Center, Texas, USA. He graduated MD cum laude from the University of Padua and undertook a post graduate specialisation in both Endocrinology and Internal Medicine. <br><br>Dr Del Prato's research interests have always been concerned with diabetes and in particular the physiopathology and therapy of type 2 diabetes and insulin resistance syndrome. He is a member of many societies and associations including the European Association for the Study of Diabetes, the American Diabetes Association, the Mediterranean Group for the Study of Diabetes and the International Diabetes Federation. He acts as referee for all major  journals. Furthermore, he has served on the Editorial Boards for the Journal of Endocrinological Investigation, Diabetes, Nutrition, and Metabolism, and the European Journal of Clinical Investigation (Diabetes and Metabolism section) and, presently, for Acta Diabetologica, Diabetes & Vascular Disease Research, Journal of Endocrinology, Diabetes/Metabolism Research & Reviews and Diabetes et Metabolism, Journal of Clinical Endocrinoloy and Metabolism. <br><br>Dr Del Prato has published over 300 articles in national and international journals and has been awarded several honours, including the Prize of the Italian Society of Diabetology for outstanding scientific activity.</td></tr></table>",
//Array 61 = Professor Pedro de Luis de Pablos-Velasco (BMS-AZ)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Professor Pedro de Luis de Pablos-Velasco</strong> <br> <i>Las Palmas University of Gran Canaria and Dr Negr&iacute;n University Hospital of Gran Canaria, Spain</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/BMS/DePablos.jpg'></td><td>Pedro Luis de Pablos-Velasco received his medical degree in 1980 at the University of Valladolid, Spain, and subsequently undertook a residency in endocrinology at the University Hospital Ram&oacute;n y Cajal, Spain. In 1990 he became Head of the Department of Endocrinology at the Dr Negr&iacute;n University Hospital of Gran Canaria, Spain. In 1993 he received his doctorate and that same year became Professor of Endocrinology at Las Palmas University of Gran Canaria, Spain.</br><br>Professor de Pablos-Velasco is a member of the Spanish Society of Endocrinology, the Spanish Society of Diabetes, the Spanish Society of High Blood Pressure, the European Association for the Study of Diabetes, and the Spanish Society of Obesity.</br><br>Professor de Pablos-Velasco has published over 49 papers in several leading peer-reviewed journals, most of them in the areas of obesity, diabetes and its complications. He is a reviewer for a number of medical journals, including Annals of Epidemiology, Obesity and Metabolism, American Journal of Hypertension, Endocrinolog&iacute;a y Nutrici&oacute;n and Revista Cl&iacute;nica Espa&ntilde;ola.<br><br></td></tr></table>",
//Array 62 = Antonio Ceriello (BMS-AZ)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Antonio Ceriello</strong> <br> <i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/BMS/Ceriello.jpg'></td><td>Antonio Ceriello is a Professor at the Institut d'Investigacions Biom&egrave;diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.<br><br>Professor Ceriello has published widely in the area of diabetes, with over 200 original papers and several book chapters to his credit. Prof. Ceriello has been a consultant to the National Institutes of Health, U.S.A (2003-2005), for the program of research related to cardiovascular disease and type 1 diabetes, and is a member of the writing committee for the American Hearth Association guidelines on 'Acute Hyperglycemia and Acute Coronary Syndromes'.<br><br>He has recently chaired the IDF committee for the development of 'Guideline for Management of Postmeal Glucose' and, currently, is the President of the EASD Study Group on 'Diabetes and Cardiovascular Diseases' and a Member of the Board of the IDF Europe. He is also serving as Associate Editor of 'Diabetes Care' and 'Diabetic Medicine'.<br><br>Prof. Ceriello is the winner of 2004 Castelli Pedroli Prize of EASD. <br><br></td></tr></table>",
//Array 63 = Jens Juul Holst, MD, PhD (BMS-AZ)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Jens Juul Holst, MD, PhD</strong> <br> <i>Professor of Medical Physiology, University of Copenhagen, Denmark</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/BMS/Holst.jpg'></td><td>Jens Holst is a professor of medical physiology at the University of Copenhagen in Denmark. He is also the vice chairman of the board of the Department of Biomedical Sciences at the University of Copenhagen and chairman of the Faculty's Research Centre for Diabetes and Obesity. He received his medical degree from the University of Copenhagen in 1970 and a Doctor of Medical Sciences degree in 1978. <br><br>Professor Holst's research has been focused on the regulatory peptides of the pancreas and gut. This has included the importance of the peptides in the regulation of the functions of the GI tract and metabolism, with particular focus on blood glucose and appetite regulation, obesity, and diabetes. He has especially conducted research on the role of incretin hormones of the gut (GLP-1 and GIP).<br><br>Professor Holst has written more than 900 full publications, including original studies, chapters in textbooks, and review articles, and is on the editorial boards of Regulatory Peptides, Endocrinology and Diabetes. He is a member of several distinguished academic organisations, including the Danish Academy for Natural Sciences and the Royal Danish Academy of Science and Letters, and has been the recipient of the Anders Jahre Award for Medical Research, the Odd Fellow Award for Medical Research, the Paul Langerhans Medal of the German Diabetes Association and the Claude Bernard award of the European Society for the Study of Diabetes.</td></tr></table>",
//Array 64 = Stephan Jacob MD, PhD (BMS-AZ)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Stephan Jacob MD, PhD</strong> <br> <i>Internist, Endocrinologist, Diabetologist , Nutrition Specialist , Clinical Hypertension Specialist (ESH), SCOPE founding fellow</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/BMS/Jacob.jpg'></td><td>Stephan Jacob is an endocrinologist/diabetologist, an expert in nutrion and a clinical hypertension specialist (ESH). He is also involved in the SCOPE programme, teaching at the University of T&uuml;bingen, Germany. He is in private practise and currently about to set up a cardio-metabolic institute (CMI), in which non pharmacological and pharmacological therapy lifestyle coaching of cardio-metabolic patients in out-patient care is coordinated. Previously, he was Senior Consultant at the Department of Endocrinology, Metabolism and Pathobiochemistry, University of T&uuml;bingen, Germany.<br><br>Dr Jacob's research interests include the aetiology of insulin resistance in first-degree relatives of patients with type 2 diabetes and first-degree relatives of patients who survived a myocardial infarction. Another focus of interest is the cardio-metabolic syndrome and the role of early detection and intervention. Finally, the effects of lifestyle intervention on prevention and treatment of co-morbidities, to set up structured care in an out-patient setting (CMI).<br><br>Dr Jacob heads the 'working group on diabetes and the heart' at the German Diabetes Association. He is currently setting up a cardio-metabolic institute and a network with GPs in  his town.</td></tr></table>",
//Array 65 = Prof. Thomas Haak (Roche)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Prof. Thomas Haak</strong> <br> <i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/Roche/Haak.jpg'></td><td>Prof. Thomas Haak has been working as chief physician at the Diabetes Clinic &ldquo;Diabetes Zentrum Mergentheim&rdquo;, Germany and has been chairing the Diabetes-Academy Mergentheim and its affiliated research institute FIDAM since the year 2000.<br><br>From 1980 &ndash; 1981 he studied economics at the Johannes-Gutenberg-University in Mainz, Germany following the study of medicine at the Johann-Wolfgang-Goethe-University in Frankfurt, Germany.<br><br>From 1987 &ndash; 1994 he specialized in Internal Medicine at the Frankfurt Medical School and became clinical diabetologist and clinical endocrinologist in 1996. <br><br>In 2001 he became professor of Internal Medicine. <br><br>From 1996 &ndash; 99 he worked as assistant medical director in a diabetes education center and in 1997 he also worked as an assistant medical director in the diabetic foot department. Also in 1997 he became the Head of the German Diabetes Association's center for training of diabetes educators, Frankfurt/Main, Germany.<br><br>From 1998 &ndash; 2000 he worked as assistant medical director in the emergency care unit.<br><br>His research interests focus on clinical research in diabetology and endocrinology with special reference to diabetic complications and pharmacological studies. He gained research experience since 1989 as investigator and principal investigator. </td></tr></table>",
//Array 66 = Dr. Peter Adolfsson (Roche)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Dr. Peter Adolfsson</strong> <br> <i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/Roche/Adolfsson.jpg'></td><td>Dr. Adolfsson has been working as a pediatrician at the Queen Silvia Children's Hospital in Gothenburg since 2001. <br><br>He was a postgraduate student at the institution for women and children's health, department of pediatrics at the Gothenburg University.<br><br>Also at the Gothenburg University he conducted his medical training from 1985 &ndash; 1990 and obtained his degree as a Medical Doctor in 1993. <br><br>In 1998 he specialized in pediatrics as well as in sports medicine. <br><br>From 1997 - 2005 he was the responsible physician for the Swedish female soccer team. Besides this, he participated in the ISPAD Science School in Boston, USA in 2005.</td></tr></table>",
//Array 67 = Prof. Mariella Trovati (Roche)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Prof. Mariella Trovati</strong> <br> <i></i><br><br></td></tr><tr><td></td><td>Mariella Trovati is full professor of Internal Medicine at the San Luigi Gonzaga Faculty of Medicine of the University of Turin and chief of the Internal Medicine and Metabolic Disease Unit at the San Luigi Gonzaga University Hospital in Orbassano (Turin), Italy.<br><br>Since 1978 Mariella Trovati is teacher at Specialization Schools of the Turin University and since 1985 she is teacher at the Medical Degree Course of the Faculty of Medicine of the Turin University.<br><br>At present, she is teaching at the Faculty of Medicine San Luigi Gonzaga both &ldquo;Medical Semiotics and Clinical Methodology&rdquo; and &ldquo;Metabolic Basis of Cardiovascular Diseases&rdquo;. Furthermore, at the same Faculty of Medicine, she is the Coordinator of the two Integrated Teachings of Clinical Methodology and Internal Medicine.<br><br>In addition she is teaching at the Specialization Schools of Internal Medicine and of Endocrinology and Metabolic Diseases of the Turin University.<br><br>Since 2000, she is in the board of the Research Doctorate in Experimental and Clinical Pharmacology and Therapeutics of the Turin University.<br><br>Prof. Trovati has been recipient of national and international research grants.<br><br>She has been invited to serve as a Referee more than 20 International Journals. She is in the Editorial Board of National and International Journals. <br><br>Prof. Trovati coordinates a research group active in the field of Diabetes, Endocrinology, and Vascular Medicine and Biology.</td></tr></table>",
//Array 68 = Dr. Lawrence Fisher (Roche)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Dr. Lawrence Fisher</strong> <br> <i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/Roche/Fisher.jpg'></td><td>Dr. Lawrence Fisher is a professor for Family and Community Medicine and Psychiatry at the University of California, San Francisco since 1984. <br><br>From 1963 &ndash; 1968 he studied Psychology at the Penn. State University, the Temple University (Philadelphia), the University of Cincinnati and the University of Colorado Medical Center. <br><br>From 1968-1969 he was USPH Post Doctoral Fellow in Psychology at the University of Colorado Medical Center, Denver, Colorado. In the years 1969 to 1979 he worked as Assistant Professor for Psychiatry and Psychology at the University of Rochester Medical School, Rochester, N.Y.<br><br>From 1979-1983 he was Associate Professor for Psychiatry and Family and Community Medicine at the University of California, San Francisco before he became professor.<br><br>Since 2004 he is also an Associate Editor for &ldquo;Diabetes Care&rdquo;.<br><br>Awards: In 1993 he was awarded with the &ldquo;AAMFT&rdquo;: Outstanding Research Publication Award.<br><br>In the years 2000 & 2002	he received the UCSF Outstanding Medical Student Teaching Award and in 2000 he was honored by the Division of Family Psychology, American Psychological Association with the &ldquo;Outstanding Contributions to the Field of Family Psychology and Health Award&rdquo;.</td></tr></table>",
//Array 69 = Dr. William Polonsky (Roche)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Dr. William Polonsky</strong> <br> <i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/Roche/Polonsky.jpg'></td><td>Dr. William Polonsky has been working as Associate Clinical Professor in the Department of Psychiatry at the University of California, San Diego since 2005.<br><br>From 1971 &ndash; 1983 he studied Psychology at the University of California, Santa Cruz as well as at the Yale University and obtained his PhD in Psychology in 1985. <br><br>He conducted his predoctoral fellowship in Clinical Health Psychology at the University of California, San Francisco, School of Medicine (Langley Porter Psychiatric Institute). In 1987 he conducted the postdoctoral fellowship in Psychosomatic Med and Psychoneuroimmunology at the Boston University School of Medicine (Departments of Psychiatry and Microbiology).</td></tr></table>",
//Array 70 = Dr. Ralph Ziegler (Roche)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Dr. Ralph Ziegler</strong> <br> <i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/Roche/Ziegler.jpg'></td><td>Dr. Ralph Ziegler has his own private practice/clinic for General Pediatrics and Pediatric Endocrinology and Diabetes (since 1993). Since 2006 he has also been working as a consultant for Pediatric Diabetes at the St. Franziskus-Hospital in M&uuml;nster, Germany.<br><br>Background: From 1979 &ndash; 1984 he studied medicine at the University of Hamburg, Germany and completed his promotion/thesis in 1986.<br><br>From 1984 &ndash; 1992 he worked as resident for pediatrics at the University-Children's-Hospital in M&uuml;nster, Germany. From 1988 &ndash; 1990 he was a research fellow at the Harvard University, Joslin Diabetes Center/Immunology in Boston/USA. From 1992 &ndash; 1993 he was employed as resident in a private practice in Warendorf, Germany.<br><br>He is a diabetologist of the DDG (German Diabetes Organisation) and specialized in Pediatric Endocrinolgy and Diabetology.</td></tr></table>",
//Array 71 = Dr. Guido Freckmann (Roche)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Dr. Guido Freckmann</strong> <br> <i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/Roche/Freckmann.jpg'></td><td>Dr. Guido Freckmann is the General Manager of the Institute for Diabetes-Technology at the University of Ulm (<a href='http://www.idt-ulm.de'>www.idt-ulm.de</a>) (since 2005).<br><br>From 1999 on he worked there as a principal physician for clinical studies.<br><br>He studied medicine from 1987 &ndash; 1994 at the Georg August University of G&ouml;ttingen and completed his thesis in 1996.<br><br>In 2005 he became member of the Glucose Monitoring Study Group (Roche Diagnostics) (www.gm-study-group.com) and member of the Advisory Board of the AGDT (study group for diabetes technologies of the German Diabetes Association) (www.diabetes-technologie.de). Since 2003 he is a 'Diabetologist DDG' of the German Diabetes Association. </td></tr></table>",
//Array 72 = Dr. Adrianne Wong (beta-cells)
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Dr. Adrianne Wong</strong> <br> <i></i><br><br></td></tr><tr><td></td><td>Dr. Adrianne Wong is currently a Senior Scientific Program Manager at the Juvenile Diabetes Research Foundation where her responsibilities in the area of Beta-Cell Replacement include the development of multidisciplinary cell therapy and non-invasive imaging programs. She is also involved in international partnerships focused on type 1 diabetes research with public and private funding agencies. Dr. Wong received her undergraduate degree in Biology from Brown University, and her doctoral degree in Cell Biology from Duke University studying cellular signaling in angiogenesis as a US Army MRMC Breast Cancer Research Program fellow with Dr. Kevin Peters. She then did postdoctoral training as an NIH NSRA fellow at Columbia University with Dr. Frank Costantini studying murine kidney development. Her scientific communication experience encompasses teaching, a production internship at National Public Radio's Science Friday and independent writing. In addition, she has expertise in intellectual property management gained as a science advisor at Darby and Darby, P.C..</td></tr></table>",
// Ab hier Speaker F.Hoffmann - La Roche Ltd.
//Array 73 = Prof. Anthony Barnett
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Prof. Anthony Barnett</strong> <br> <i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/f_hoffmann/Barnett.jpg'></td><td>Anthony (Tony) Barnett is Professor of Medicine at The University of Birmingham and heads one of the biggest diabetes/endocrine units in the UK at the Heart of England NHS Foundation Trust, Birmingham. He has major research interests in genetics of diabetes and its microangiopathic complications, etiology of diabetic vascular disease, pathogenesis of type 2 diabetes, new drugs for diabetes and its vascular complications, and health service-related issues, including provision of diabetes care in the South Asian population. His main clinical interest is in cardiovascular disease in association with diabetes. He has published over 500 original research papers and has edited major textbooks of diabetes as well as contributing to <u>Textbook of Diabetes</u>, <u>International Textbook of Diabetes Mellitus and Encyclopaedia of Molecular Biology and Molecular Medicine</u>. He also edits or has edited several educational journals aimed at primary care, including <u>Modern Hypertension Management</u>, <u>Modern Diabetes Management</u>, <u>Obesity in Practice</u>, and <u>Practical Cardiovascular Risk Management</u>.<br>He was recently awarded the Banting Memorial Lecture for 2011, the highest award from Diabetes UK</td></tr></table>",
//Array 74 = Prof. Jaime Davidson M.D., F.A.C.P., M.A.C.E.
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:750px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Prof. Jaime Davidson M.D., F.A.C.P., M.A.C.E.</strong><br><br><br></td></tr><tr><td><img src='../images/symposia/speakers/f_hoffmann/Davidson.jpg'></td><td>He is a Clinical Professor of Internal Medicine at the University of Texas Southwestern Medical Center, Division of Endocrinology and a member of the executive committee on CME.  He has been a Council member for the Texas Department of Health Services.  He is also  the president of WorldWIDE Diabetes, a non for profit diabetes international medical education entity.  He serves in the task force of the National Quality Forum on Diabetes.  His previous experience includes  past president of Endocrine &amp; Diabetes Associates of Texas, member of the National Diabetes Advisory Board, National Institutes of Health, Chair Texas Diabetes Council, Texas Department of Health, Board of Directors of the American Diabetes Association where he serve in different positions and chair the Minority Task Force.  He is a member of the Endocrine Society and has served in the Minority Committee.  Dr. Davidson was one of the charter members in the formation of the American Association of Clinical Endocrinologists, and served 3 consecutive terms as a member of the board of directors.  He chair the Diabetes Guidelines in 2001 and the initial road map for the prevention and treatment of Type 2 Diabetes.  Recently this guidelines where updated and he again co chair the group.  The road map update is now published in Endocrine Practice, May/June 2007.   He has served as a Trustee of the American College of Endocrinology, as member of the Texas Diabetes Council Professional Committee for the Texas Department of Health, a member of the Council on Obesity Diabetes Education, the International Diabetes Federation Task Force on Epidemiology, and  the President&rsquo;s Council on Physical Fitness and Sports.  He served in higher education as a Regent for Midwestern State University, Texas and as a Committee Member of the National Academies , Institute of Medicine&rsquo;s &ldquo;Identifying Priority Areas for Quality improvement.<br>He has received numerous awards including the IDF SACA Region Hagedorn Award, the Yank D. Coble, Jr Award from the American College of Endocrinology and the Alberto Housay, MD award from Minority Health.<br>Most recently he was presented with the Outstanding Service Award for the Promotion of Endocrine Health of an Underserved Population for his work in addressing health disparities in Hispanic and Latino communities during the 2006 annual meeting of the American Association of Clinical Endocrinologists an the prestigious Harold Rifkin, MD Award from the American Diabetes Association for his contributions to diabetes not only in the United States but globally.<br>In 2007 he was recognized by the Mexican Academy of Medicine and honored as an honorary member of the Academy during his presentation &ldquo;Diabetes from an Art to a Science with Art&rdquo;.<br>In 2008 The American College of Endocrinology  honored him making him &ldquo;Master of the American College of Endocrinology&rdquo;.<br>He has over 100 publications including some chapters in textbooks,  and in addition chair the &ldquo;New Onset Diabetes After Transplantation Guidelines&rdquo; for the International Diabetes Federation and served in the Postprandial Glucose Control Guidelines.  He served  as well in the IDF Self Glucose Monitoring Guidelines and now in the development of new treatment guidelines for patients with Type 2 Diabetes.<br>He is the co-director of the &ldquo;Curso Intensivo Anual de Diabetes, Endocrinologia y Enfermedades Metabolicas&rdquo; from the University of Southern California, Keck School of Medicine, this year will mark the 12th  consecutive year with an attendance of 300 plus Endocrinologists of Spanish speaking countries as well as the USA.<br>He is now serving his second term as an advisor to the American Association of Clinical Endocrinologists.</td></tr></table>",
//Array 75 = Prof. Itamar Raz M.D.
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Prof. Itamar Raz M.D.</strong> <br> <i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/f_hoffmann/Raz.jpg'></td><td>Professor Itamar Raz, is head of The Hadassah Diabetes Center, President of the Israel Diabetes Research Group, head of the National Board/Task Force on Diabetes of the Israel Ministry of Health, former President of the Israel Diabetes Association, Chairman of DIRECT – Diabetes International Research and Education Cooperation Team, Representative for Europe in the International Diabetes Federation and active Chair and Lecturer in the European Association for Diabetes. Professor Raz has published over 150 research papers and holds editorial positions on a number of medical journals.<br>Professor Raz graduated from Hebrew University & Hadassah School of Pharmacy with a Bachelor of Science in 1973, In 1981 he graduated from Hebrew University & Hadassah School of Medicine with an M.D. and completed his residency at Hadassah University Hospital from 1981-1985, specializing in internal medicine. Professor Raz's medical career began in 1985 at Hadassah University Hospital as Senior Physician, specializing in Internal Medicine and that same year, he began lecturing on diabetes at the hospital's Department of Internal Medicine. From 1986-1992 Professor Raz was head of Hebrew University Student Services, and in 1988 was appointed Senior Lecturer at Hadassah University Hospital's Department of Internal Medicine, specializing in diabetes. In 1989 Professor Raz was appointed Chief Physician of Internal Medicine and Diabetes, and Head of the Diabetes Clinic at Hadassah University Hospital in 1992. In 1995, Professor Raz became an Associate Professor at the Department of Internal Medicine, Hadassah University Hospital, until 2001, when he was appointed Director of the hospital's Center for Prevention of Diabetes and its Complications, a position he holds until today. Since 2003, Professor Raz has also been Professor of Diabetes at the Department of Internal Medicine, Hadassah University Hospital.<br>With unlimited dedication and commitment, Professor Raz has been at the vanguard of Israel's diabetes research for the last 19 years, leading it through numerous breakthroughs and spearheading collaborative efforts with other major research institutes. He has devoted his professional life to the study and care of diabetes and its complications.</td></tr></table>",
//Array 76 = Prof. Wolfgang Schmidt
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Prof. Wolfgang Schmidt</strong> <br> <i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/f_hoffmann/Schmidt.jpg'></td><td>Professor Wolfgang E. Schmidt studied Medicine and some Chemistry at the Universities of Kiel and Goettingen, Germany. He completed his Ph.D. at the Max-Planck-Institute of Experimental Medicine in Goettingen. He was a postdoctoral research fellow at the Karolinska Institute, Stockholm, with Prof. Viktor Mutt, at the University of Goettingen Medical School with Prof. Werner Creutzfeldt and at the Massachusetts General Hospital, Harvard Medical School, Boston, with Prof. Dan Podolski. Since 1998, he is Professor of Medicine, Gastroenterology and Diabetology (Chair), Chief of GI/Hepatology and Diabetes Services and Director of the Department of Medicine I at the St. Josef-Hospital, Ruhr-University of Bochum Medical School. His clinical and research areas are: incretins, entero-insular axis, gastrointestinal hormones; Type 2 Diabetes: pathophysiology, islet cell dysfunction, novel therapies; fatty liver disease; acute and chronic pancreatitis; pancreatic cancer and gastrointestinal oncology. Professor Schmidt is currently Editor-in-Chief of &rdquo;Regulatory Peptides&ldquo; and a member of several Editorial Boards of scientific journals. He received 17 scientific awards and published more than 290 original peer-reviewed papers.</td></tr></table>",
// Ab hier Speaker Daiichi Sankyo
//Array 77 = Hermann Haller
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Hermann Haller</strong> <br> <i>Medizinische Hochschule, Hannover,  Germany</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/daiichi/Haller.jpg'></td><td>Hermann Haller received his degree in  medicine in 1982 from the Free University, Berlin, Germany  and subsequently joined the University Clinic Benjamin Franklin,  Berlin-Steglitz. In 1993, he became Coordinator of Hypertension Research at the  Max Delbr&uuml;ck Centre for Molecular Medicine, Berlin-Buch,  Germany, and in 1999 he  became Director of the Department of Nephrology, Medizinische Hochschule  Hannover, Hannover, Germany. He was Chairman of the Department  of Internal Medicine from 2001 to 2005 and since 2003 Professor Haller has been  Dean of Student Education at the Medizinische Hochschule Hannover.<br>Professor  Haller&rsquo;s research interest is the vascular biology of acute and chronic renal  diseases, including mechanisms of transplant nephropathy, diabetic nephropathy,  hypertension and chronic inflammation, and organ damage. He has published more  than 400&nbsp;original articles and reviews, and he is on the editorial boards  of several international journals.Professor  Haller&rsquo;s research has led to many honours, including the Franz Volhard Prize of  the Society of Nephrology, the Walter Clawitter Prize of the Heinrich Heine  University, D&uuml;sseldorf, the Galenus-von-Pergamon-Preis, and the Bjorn Folkow  Award of the European Society of Hypertension.</td></tr></table>",
//Array 78 = Josep Redon
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Josep Redon</strong> <br> <i>Hospital Clinico, University of Valencia, Valencia, Spain</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/daiichi/Redon.jpg'></td><td>Josep Redon graduated in medicine from the Medical  School at the University of Valencia, Valencia, Spain. He is a specialist in  internal medicine, a Research Fellow in Hypertension for the Northwestern  University Medical School of Chicago, Chicago, Illinois, USA, and a Fellow of  the Council for High Blood Pressure of the American Heart Association. He has  also established a research unit dedicated to studying the mechanisms of  hypertension-induced organ damage.<br>Professor Redon is currently Professor of Medicine, Head  of Internal Medicine and Coordinator of the Hypertension Unit, Hospital  Clinico, at the University of Valencia, Scientific Director of the Research  Institute INCLIVA and Vice-President of the European Society of Hypertension.  He is also a member of the European Working Group on Ambulatory Blood Pressure  Monitoring; a member of the Board of the Network for Cardiovascular Research of  the Instituto de Salud, Carlos III (Health Ministry); and former President of  the Spanish Society of Hypertension.<br>Professor Redon has lectured widely at local,  national and international levels. He has authored numerous papers and is a  member of the editorial boards of several journals in the field of hypertension. </td></tr></table>",
//Array 79 = Luis M. Ruilope
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Luis M. Ruilope</strong> <br> <i>Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/daiichi/Ruilope.jpg'></td><td>Luis Ruilope is  Associate Professor of Internal Medicine at Complutense  University and Head of the  Hypertension Unit at the Hospital 12 de Octubre in Madrid, Spain.  His principal area of interest is hypertension and the kidney. Professor  Ruilope received his MD degree from the University  of Madrid and completed his residency  and fellowship in nephrology at the Jim&eacute;nez D&iacute;az Foundation in Madrid.<br>A member  of the Scientific Council of the International Society of Hypertension (ISH)  and an International Fellow of the Council of High Blood Pressure Research, Professor  Ruilope is on the editorial boards of the <em>Journal of Hypertension</em>, <em>Blood  Pressure</em>, <em>High Blood Pressure &amp; Cardiovascular Prevention</em>, <em>Medicina  Clinica</em>, <em>Nephrology</em> <em>Dialysis Transplantation</em>, and the <em>Journal  of Human Hypertension</em>.<br>Professor Ruilope is a board member of the  Spanish Society of Hypertension and a member of the Council on the Kidney in  Cardiovascular Disease (American Heart Association). He served on the ISH 2000  International Scientific Program Committee and was a member of the Steering  Committee for the studies: Hypertension Optimal Treatment (HOT); Intervention as  a Goal in Hypertension (INSIGHT); Study on COgnition and Prognosis in the  Elderly (SCOPE); and Controlled ONset Verapamil INvestigation of Cardiovascular  Endpoints (CONVINCE).</td></tr></table>",
//Array 80 = Giancarlo Viberti
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Giancarlo Viberti</strong> <br> <i>King&rsquo;s College London School of Medicine, London, UK</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/daiichi/Viberti.jpg'></td><td>Giancarlo  Viberti is Emeritus Professor of Diabetes and  Metabolic Medicine, and former Director  of the Unit for Metabolic Medicine, King&rsquo;s College London School of Medicine, London, UK.  He received his MD in 1968 from the University   of Milan, after which he  specialised in Endocrinology at the University of Turin, Italy. In 1978,  Professor Viberti was awarded a Wellcome Senior Research Fellowship in Clinical  Science, and became a member of the Royal College of Physicians in 1985,  followed by a Fellowship in 1990.<br>Professor  Viberti received the Robert Campbell medal of the Ulster Medical Society in  1986. He has also been the Camillo Golgi Lecturer and Pedroli Prize winner of  the European Association for the Study of Diabetes; 2000 Banting Lecturer of  the British Diabetic Association; 2003 Areteus Lecturer of the Pan Hellenic  Diabetes Society; 2004 Ruth &Oslash;sterby Lecturer of the European Diabetic  Nephropathy Study Group; and 2006 Alan Nabarro Lecturer of the International  Diabetes Federation.<br>A frequent  speaker at national and international meetings, a Visiting Professor at  universities worldwide and an active researcher, clinician and lecturer,  Professor Viberti&rsquo;s major research interests include the study of kidney  disease and vascular complications in diabetes. He has published more than 240  original papers and 160 reviews, editorials and book chapters.</td></tr></table>",
//Array 81 = Vincenza Cifarelli 
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Vincenza Cifarelli </strong> <br> <i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/c-peptide/Cifarelli.jpg'></td><td>Vincenza Cifarelli is a doctoral student in Human Genetics at University of Pittsburgh Medical Center. She holds a degree in Bioscience and Biotechnology from the University of Modena, Italy. Her research focuses on vascular complication and endothelial dysfunction during inflammation. Dr. Cifarelli is currently studying the potential role of C-peptide in preventing vascular damage from Type 1 Diabetes.</td></tr></table>",
//Array 82 = Michaela Diamant, MD, PhD
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Michaela Diamant, MD, PhD</strong> <br> <i>Professor<br>VU University Medical Center, Amsterdam, The Netherlands</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/Lilly/Diamant.jpg'></td><td>Michaela Diamant is Professor of Diabetology and Director of the Diabetes Center at the VU University Medical Center (VUMC) in Amsterdam, The Netherlands. She received her MD degree in 1987 from Leiden University. After graduation, she worked as a PhD student at the Rudolf Magnus Institute for Pharmacology, Utrecht University under the supervision of the late Professor David de Wied. In 1991, she completed her PhD thesis, entitled 'Neuropeptides, Autonomic Stress Responses and Behavior'. From 1992 to 2000, she received specialty and sub-specialty training in internal medicine, nephrology and endocrinology at the Academic Medical Center, University of Amsterdam and Leiden University Medical Center. In 2000, Professor Diamant joined the Diabetes Center at VUMC (then headed by Professor Robert Heine). <br><br>In addition to her work as a clinical diabetologist, she supervises multiple research projects, both clinical and experimental, with a main focus on pathogenesis of type 2 diabetes and mechanisms of cardiovascular disease in type 2 diabetes. Professor Diamant has received research support from organisations including the Dutch Diabetes Research Foundation, Dutch Heart Foundation, The Netherlands Heart Foundation and the EU, and has authored or co-authored over 170 original research papers, reviews, chapters and patents. She has served as Honorary Secretary and Chair of the Board of the Dutch Association for Diabetes Research, and is currently a member of the Scientific Board of the Dutch Diabetes Research Foundation, a core-member of the Scientific Advisory Group for Diabetes and Endocrinology (CHMP/EMA) and a member of the Expert Advisory Board for DIAMAP/EURADIA. She is a member of the editorial board of Diabetologia, Cardiovascular Diabetology, Clinical Medicine: Endocrinology and Diabetes and the Journal of Clinical Metabolism and Diabetes, and serves on the EASD Panel for overseeing guidelines and statements and the EASD 2010 Programme Committee. </td></tr></table>",
//Array 83 = Geremia B. Bolli, MD
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Geremia B. Bolli, MD</strong> <br> <i>University of Perugia, Perugia, Italy</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/sanofi-aventis/Bolli.jpg'></td><td>Prof. Geremia Bolli graduated from Perugia University School of Medicine. After training in cardiology and internal medicine at Pisa and Perugia University Schools of Medicine, respectively, Prof. Bolli trained in endocrinology at the Mayo Clinic. He returned to the University of Perugia, where he is Professor of Medicine and Director of the internal medicine and diabetes clinic. Prof. Bolli has served on numerous scientific committees and is a member of several societies, including EASD and ADA. Prof. Bolli's research interests have included the physiology of glucose counter-regulation to hypoglycaemia and the pathophysiology of hypoglycaemia. He has studied the pharmacokinetics and pharmacodynamics of insulin preparations, including rapid- and long-acting insulin analogues, and established models of intensive insulin therapy for diabetes treatment. Prof. Bolli's current interest is the long-term optimisation of glycaemic control in type 1 and type 2 diabetes.</td></tr></table>",
//Array 84 = Philip Home, MA, DPhil, DM, FRCP
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Philip Home, MA, DPhil, DM, FRCP</strong> <br> <i>Newcastle University, Newcastle upon Tyne, UK</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/sanofi-aventis/Home.jpg'></td><td>Philip Home is Professor of Diabetes Medicine at Newcastle University, and Consultant Physician in Diabetes and Metabolic Medicine at the Newcastle Diabetes Centre and Newcastle Hospitals. Professor Home is Vice-Chair of the National Institute of Clinical Excellence (NICE) Appraisal Committee, the UK drug reimbursement advisory committee, and has been Clinical Lead to UK (NICE) and International Diabetes Federation (IDF) clinical guidelines for diabetes. He was previously President of IDF Europe and Vice-President of the IDF, and was the Programme Committee Lead for the IDF World Diabetes Congress in Montreal. His major research interest is new therapies for diabetes management, both insulin and oral agents, and he has published extensively in these and related areas.</td></tr></table>",
//Array 85 = Martin Pfohl, MD, PhD
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Martin Pfohl, MD, PhD</strong> <br> <i>Ruhr University, Bochum, Germany</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/sanofi-aventis/Pfohl.jpg'></td><td>Martin Pfohl is Associate Professor of Medicine at the Ruhr University in Bochum and Head of the Department for General Internal Medicine, Diabetes and Endocrinology at the Bethesda-Johanniter- Klinikum in Duisburg, Germany. His published research includes studies on genetic risk factors of diabetic macroangiopathy and studies on the regulation of lipid metabolism. His current research interests focus on clinical studies in diabetes, i.e. insulin therapy and insulin analogues, and on the improvement of long-term diabetes control. Professor Pfohl is a regular reviewer and member of the editorial boards of several diabetes journals and has published widely in the area of diabetes, with over 70 original papers and many book chapters and books.</td></tr></table>",
//Array 86 = Andreas Pf&uuml;tzner, MD, PhD
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Andreas Pf&uuml;tzner, MD, PhD</strong> <br> <i>Institut f&uuml;r Klinische Forschung &amp; Entwicklung (IKFE), Mainz, Germany</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/sanofi-aventis/Pfuetzner.jpg'></td><td>Prof. Dr. Andreas Pf&uuml;tzner studied Medicine and Chemistry in Mainz and Frankfurt, Germany (1979-1986, MD in oncology, PhD in protein chemistry). He later joined the pharmaceutical industry in 1992 where he held several leading positions before founding the IKFE in Mainz, Germany, in 1998. Since April 2000, he has been full-time CEO of IKFE, an ISO-certified clinical research institute with clinical units, laboratory, CRO and training academy, with focus on diabetes and cardiovascular disease, and additionally became Professor of Applied Clinical Research at the University of Applied Sciences, Rheinbach, Germany in 2001. He has published about 500 full papers, abstracts and book articles (mainly on diabetes and AIDS research) and is on the editorial board of several scientific journals. Prof. Pf&uuml;tzner is member of the scientific advisory boards of the German Diabetes Foundation, Munich, the German Association of Healthcare Insured Patients, Berlin, and the Academy of Integrated Interdisciplinary Medicine, Wiesbaden.</td></tr></table>",
//Array 87 = Ele Ferrannini, MD
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Ele Ferrannini, MD</strong> <br> <i>University of Pisa, Pisa, Italy</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/sanofi-aventis/Ferrannini.jpg'></td><td>Ele Ferrannini is Professor of Internal Medicine at the University of Pisa and Adjunct Clinical Professor at the Diabetes Division, University of Texas Health Science Center. After graduating from the University of Pisa, he specialised in Nuclear Medicine and Diabetes and Metabolic Diseases. Professor Ferrannini's fields of expertise are the pathophysiology of hyperglycaemia, insulin resistance and &beta;-cell function, mathematical modelling of glucose and insulin metabolism, and the clinical course and pathophysiology of cardiovascular complications of diabetes. He has contributed over 450 original papers and 50 book chapters and is on the list (ISIHighlyCited.com) of highly cited scientists.</td></tr></table>",
//Array 88 = Emma Lindahl, M.Sc.
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Emma Lindahl, M.Sc.</strong> <br> <i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/c-peptide/Lindahl.jpg'></td><td>Emma Lindahl has been working on C-peptide the past five years together with professor Jörnvall and she will defend her thesis later this year at Karolinska Institutet. She holds a M. Sc. from Southern College of Stockholm with majors in biochemistry and analytical chemistry. Apart from her research, Emma is has been very active in entreprenuerial activities at Karolinska Institutet. </td></tr></table>",
//Array 89 = James Callaway, Ph. D.
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>James Callaway, Ph. D.</strong> <br> <i></i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/c-peptide/Callaway.jpg'></td><td>Dr. Callaway received his Ph. D. in Biological Chemistry at UCLA while applying protein chemistry to the study of histone subunit interactions with in chromatin. <br>He proceeded to apply his biochemistry background to the study of bactericidal peptides at Ingene (now Xoma) before moving to SmithKline Beecham (now GSK) to work on the development of recombinant flu and malaria vaccines as well as therapeutic proteins and antibodies. He then joined Bayer to help develop and secure world-wide approval for the first recombinant Factor VIII molecule to treat hemophilia.<br>Jim then joined Athena Neurosciences (now Elan) and was instrumental in the pharmaceutical development activities to support Tysabri&reg;. In addition, he led the  program to develop Myobloc&reg; and secure approval of the BLA/PLA/MAA while serving as the lead accountable person in the design, construction, validation, and FDA approval of a biologics manufacturing plant.  He also was the Program Executive for the Alzheimer's Immunotherapy (bapineuzumab is the lead compound) program for nearly a decade, advancing it from IND filing to Phase 3 design. During his tenure at Elan, Jim was responsible for significant line function responsibilities including a worldwide Development organization of 200-plus scientists.<br>Currently Dr. Callaway is the President of R&D for Cebix Incorporated, where the team is advancing C-peptide as a therapeutic to treat and prevent the long-term complications of type 1 diabetes.<br> My other key area of accountability, which I have dispatched in parallel with my line responsibility over the past decade, has been as Project Leader.  In this role I have assembled and led teams in both and strong and weak matrix fashion to deliver IND filings, numerous clinical trials, and an NDA-MAA approval.  This role also required that I deliver on major corporate assets to the corporation through leadership in the absence of direct line accountability, under confounding circumstances such as the presence of a large corporate partner.  This role also expanded my accountability beyond traditional scope of development to early Research activities within the Alzheimer's Disease field as well as establishment of strategies to maximize the commercial opportunity requiring an annual budget of over &#36; 100 MM.  This development effort has a commercialization team fully integrated into the process to assure optimal data are generated and product positioning is achieved prior to approval.  I am currently responsible for all aspects of Elan's Alzheimer's immunotherapy programs, an area in which Elan retains industry leadership.<br>I am confident that small innovative companies which focus on their science while integrating sound development strategies will continue to be the engine through which the majority of important innovative therapeutics are identified, validated and ultimately commercialized.  By delivering on these objectives efficiently, such companies will also create substantial shareholder value.</td></tr></table>",
//Array 90 = Dr Karen E. Porter, BSc (Hons), PhD.
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Dr Karen E. Porter, BSc (Hons), PhD.</strong> <br> <i></i>Reader in Cardiovascular Cell Biology<br>Leeds Institute of Genetics, Health and Therapeutics<br>University of Leeds, Leeds, UK <br></td></tr><tr><td><img src='../images/symposia/speakers/c-peptide/Porter.jpg'></td><td><b>Background</b><br>My research group studies vascular remodelling, and we have a particular interest in understanding the mechanisms underlying failure of saphenous vein bypass grafts. Working exclusively in human tissues and cells for almost two decades, we have undertaken laboratory studies into the causes of graft failure, evaluated potential therapeutic targets and elucidated underlying mechanisms. Indeed, a number of years ago we revealed that statins, widely prescribed cholesterol-lowering drugs could be beneficial to patients having coronary bypass grafts. Their beneficial effects on the vascular smooth muscle cell (VSMC) were found to be independent of cholesterol-lowering &ndash; known as 'pleiotropic' effects. <br><br><b>Current Interests</b><br>My interest in the macrovascular complications of diabetes has evolved in recent years. Approximately 2.5 million people in the UK have Type 2 diabetes and around 80 percent of these individuals will die of a cardiovascular event. Elucidating underlying pathological mechanisms is key to developing new therapeutic targets. Intensive control of hyperglycaemia retards diabetic microvascular complications (retinopathy, nephropathy and neuropathy) but beneficial macrovascular effects (coronary atherosclerosis) are less apparent. In diabetic patients, the long-term outcomes of coronary revascularisation are disappointing, irrespective of the mode &ndash; angioplasty, stenting or coronary artery bypass grafting.  My presentation will provide evidence that insulin therapy, whilst effectively controlling glycaemia in diabetic patients, may play a causative role in  saphenous vein bypass graft failure. Importantly, I will present data proposing that co-administration of proinsulin C-peptide has potential to ameliorate the harmful effects of insulin at the level of the VSMC. The potential role of the transcription factor SREBF1 in this mechanism will be considered.</td></tr></table>",
//Array 91 = Lina Nordquist, M.Sc., PhD
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Lina Nordquist, M.Sc., PhD</strong> <br> <i></i><br></td></tr><tr><td><img src='../images/symposia/speakers/c-peptide/Nordquist.jpg'></td><td>Lina Nordquist received her M.Sc. in pharmacy, M.Pharm.Sc, and Ph.D. degree in physiology from Uppsala University in Uppsala, Sweden, in 2001, 2002, and 2007, respectively. She has published more than 20 research papers and is currently funded by the Swedish Society for Medical Research. Among her awards are the Sixten Gemz&eacute;us Award, the Swedish Renal Medicine Award and the Rolf Luft Award.<br>Nordquist's research is devoted to renal complications from diabetes mellitus. Ongoing research uses in vitro approaches and whole animal preparations to investigate the roles of C-peptide deficiency and metabolic alterations in renal physiology. Similar approaches focus on elucidating the contributions of tissue hypoxia and oxidative stress in the development of diabetic nephropathy. </td></tr></table>",
//Array 92 = Nikolaus Marx
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Nikolaus Marx</strong> <br> <i></i><br></td></tr><tr><td><img src='../images/symposia/speakers/c-peptide/Marx.jpg'></td><td>Nikolaus Marx, born in 1968, is Professor of Medicine / Cardiology and Head of the Department of Internal Medicine I, University Hospital Aachen, Germany.  He received his medical training at the Universities of Mainz, Genf (Switzerland) and D&uuml;sseldorf, obtaining his MD in 1994. His thesis on growth regulation in human renal cancer cell lines was completed at the laboratory of Professor Gerharz at the Institute of Pathology, University of Mainz. After a post-doctoral fellowship with Dr. Peter Libby and Dr. Jorge Plutzky at Brigham and Women's Hospital, Harvard Medical School, Nikolaus Marx later became a board-certified internist, then cardiologist, before specialising in intensive care medicine in internal medicine at the University of Ulm. He was appointed Professor of Medicine / Cardiology and Head of the Department of Internal Medicine I at the University of Aachen in 2009.<br>Professor Marx is a member of several organisations within the field of cardiology and diabetes, including the European Society of Cardiology, American Heart Association (AHA), German Diabetes Association and the European Association for the Study of Diabetes. In addition to reviewing submitted manuscript to numerous journals, including Circulation, Diabetologia, Diabetes, Diabetes Care, the Journal of Immunology and The Lancet, he is currently Associate Editor for Diabetes and Vascular Disease Research. Professor Marx was awarded the Servier Young Investigators Award in 1999 at the First European Meeting on Vascular Biology and Medicine more recently was winner of the Poster Award Competition in Epidemiological Science at AHA 2002, the 2004 Morgagni Young Investigator Award as well as the Rising Star Award 2005 of the European Association for the Study of Diabetes (EASD).</td></tr></table>",
//Array 93 = Maren R. Laughlin
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Maren R. Laughlin</strong> <br> <i>National Institute of Diabetes and Digestive and Kidney Diseases<br>National Institutes of Health<br>Bethesda, MD  / USA</i><br></td></tr><tr><td><img src='../images/symposia/speakers/beta-cells/Laughlin.jpg'></td><td>Dr. Laughlin earned an AB from Oberlin College and a Ph.D. in Chemistry from Yale University.  She completed a senior staff fellowship at the National Heart, Lung and Blood Institute and joined the faculty of The George Washington University Medical School.  Currently she is a Senior Advisor at the National Institute of Diabetes and Digestive and Kidney Diseases in Bethesda, MD, with an adjunct research appointment at Johns Hopkins University.<br><br>Her research has focused on the measurement of intermediary metabolic pathways using NMR and light spectroscopy, particularly glucose and glycogen metabolism in heart, liver and muscle.  As a program official at the NIH, her current work lies in supporting research to understand metabolic disease, particularly the application of imaging and isotopic tracer approaches to outstanding questions in diabetes and obesity.  Although imaging is starting to be used in these fields, one doesn't yet find the widespread acceptance of the technology found in cancer research and in the neurosciences. </td></tr></table>",
//Array 94 =  Vivian A. Fonseca
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Vivian A. Fonseca, MD, FRCP</strong><br><i>Tulane University Medical Center, New Orleans, USA</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/sanofi-aventis/Fonseca.jpg'></td><td>Vivian A. Fonseca is Professor of Medicine, the Tullis-Tulane Alumni Chair in Diabetes, and Chief of the Endocrinology Division at Tulane University Medical Center in New Orleans, Louisiana. He is currently Vice–President of Science and Medicine of the American Diabetes Association. He has been Editor-in-Chief of Diabetes Care since 2007 and has served on the editorial board or as a reviewer for numerous journals. Professor Fonseca is a fellow of the American Association of Clinical Endocrinologists, the Royal College of Physicians (London), and the American College of Physicians, and serves on several national and international committees. He has published over 200 articles and his current research interests include the prevention and treatment of diabetic complications and risk factor reduction in cardiovascular disease. </td></tr></table>",
//Array 95 =  Christian Boitard, MD
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Christian Boitard, MD</strong><br><i>INSERM, Paris, France</i><br><br></td></tr><tr><td><img src='../images/symposia/speakers/sanofi-aventis/Boitard.jpg'></td><td>Christian Boitard is Professor of Clinical Immunology and Director of the Institute of Circulation, Metabolism and Nutrition at the INSERM, Paris, France. After receiving his doctoral degree from Caen University, France, Professor Boitard carried out internships in Rouen and Paris, before undertaking post-doctoral research at the Department of Medical Microbiology at Stanford University, Palo Alto, USA. He returned to France to work at Necker Hospital, Paris, and was later appointed Professor of Clinical Immunology at Paris-Descartes University. Professor Boitard then became Director of INSERM Unit 561 at Cochin Hospital, before taking up his current position in 2008. His research focuses mainly on T-cell responses to proinsulin 1 and 2 both in mouse models for type 1 diabetes and in people with diabetes. Professor Boitard has received several awards for his work and has widely published in this area of research.</td></tr></table>"






// :::::::::: Texte f&uuml;r die Info-Box bis hier
);


overdiv="0";


function popLayer(a)
{
if(!descarray[a]){descarray[a]="<font color=red>Dieses PopUp (#"+a+") ist nicht korrekt definiert - Beschreibung fehlt</font>";
}

desc = "<table style='border:1px solid #5F5F5F' cellspacing=0 cellpadding=10 border=0><tr><td style='font-size:11px;color:#000000;background-color:#F8F8F8'>\n"
        +descarray[a]
        +"\n</td></tr></table>";
if(navigator.family =="nn4") {
        document.object1.document.write(desc);
        document.object1.document.close();
        document.object1.left=x+15;
        document.object1.top=y-5;
        }
else if(navigator.family =="ie4"){
        object1.innerHTML=desc;
        object1.style.pixelLeft=x+15;
        object1.style.pixelTop=y-5;
        }
else if(navigator.family =="gecko"){
        document.getElementById("object1").innerHTML=desc;
        document.getElementById("object1").style.left=x+15;
        document.getElementById("object1").style.top=y-5;
        }
}


//  versteckt die PopUp-Box
function hideLayer(){
if (overdiv == "0") {
        if(navigator.family =="nn4") {eval(document.object1.top="-500");}
        else if(navigator.family =="ie4"){object1.innerHTML="";}
        else if(navigator.family =="gecko") {document.getElementById("object1").style.top="-500";}
        }
}


//  &uuml;berwacht Maus-Position / plaziert die Box dementsprechend
var isNav = (navigator.appName.indexOf("Netscape") !=-1);

function handlerMM(e){

// entweder feste x/y-Position f&uuml;r die Info-Box
// x = 300; // Infobox x-Position bei 300 von links
// y = 0;   // Infobox y-Position bei 0 (oben)
// oder Plazierung neben Mauszeiger


x = (isNav) ? e.pageX : event.clientX + document.body.scrollLeft;
y = (isNav) ? e.pageY : event.clientY + document.body.scrollTop;

}

if (isNav){document.captureEvents(Event.MOUSEMOVE);}
document.onmousemove = handlerMM;
//  End -->
